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Glossary
ADl – activities of daily living, AF – atrial fibrillation; BMi – 
body mass index; Bp – blood pressure; CAS – carotid angioplasty 
and stenting; CeA – carotid endarterectomy; Ci – confidence 
interval; CSF – cerebrospinal fluid; CT – computed tomography; 
Cv – cardiovascular; DSA – digital subtraction angiography; DvT 
– deep-vein thrombosis; DWi – diffusion-weighted imaging; eCG 
– electrocardiography; eMS – emergency medical services; eSr 
– erythrocyte sedimentation rate; GCp – good clinical practice; 
HDl – high-density lipoprotein; Hiv – human immunodeficiency 
virus; inr – international normalised ratio; lDl – low-density 
lipoprotein; MCA – middle cerebral artery; MrA – magnetic 
resonance angiography; Mri – magnetic resonance imaging; mrS 
– modified rankin score; MDT – multi-disciplinary team; nASCeT 
– north American Symptomatic Carotid endarterectomy Trial; nG 
– nasogastric; niHSS – national institutes of Health Stroke Scale; 
ninDS – national institute of neurological Disorders and Stroke; 
nnT – numbers needed to treat; OSA – obstructive sleep apnoea; 
Or – odds ratio; OT – occupational therapy; pe – pulmonary 
embolism; peG – percutaneous enteral gastrostomy; pFO – patent 
foramen ovale; rCT – randomised controlled trial; rr –relative risk; 
SASpi – Southern African Stroke prevention initiative study; SASS 
– South African Stroke Society; SSris – selective serotonin reuptake 
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Background. Stroke is a leading cause of death and disability in 
South Africa. An increase in the burden of stroke is predicted as 
the population is undergoing a rapid epidemiological transition 
with increased exposure to, and development of, stroke risk factors, 
together with aging of the population.
Objective. The objective was to update the guideline published 
in 2000, to place the recommendations within the current South 
African context, and to grade evidence according to the level of 
scientific rigour.
Recommendations. ideally, all patients with acute stroke should be 
managed in a dedicated stroke unit. There is ample evidence that 
protocol-driven multidisciplinary stroke unit care within a hospital 
improves recovery from stroke. Treatment in a stroke unit has 
been shown to reduce mortality as well as reduce the likelihood 
of dependency after stroke. An effective stroke service requires 
the establishment of a seamless network consisting of acute stroke 
units, post-acute care and rehabilitation, and further care in the 
community.
primary preventive measures reduce stroke incidence and should 
be universally available and actively promoted at all levels of health 
care in South Africa. Successful care of a stroke patient begins 
with recognition by the public and health professionals that stroke 
should be considered an emergency. Avoiding delay should be the 
major aim of the prehospital phase of acute stroke care. Acute stroke 
or transient ischaemic attack (TiA) should be treated as a medical 
emergency and evaluated with minimum delay. General supportive 
treatment is emphasised and is directed at maintaining homeostasis 
and the treatment of complications. intravenous thrombolytic 
therapy with recombinant tissue plasminogen activator (tpA) is 
an accepted therapy for acute ischaemic stroke within 4.5 hours of 
onset of symptoms, but can only be administered at centres with 
specific resources.
Awareness and treatment of the neurological and systemic 
complications of acute stroke are an integral part of management. 
patients with suspected TiA and minor stroke with early spontaneous 
recovery should be evaluated as soon as possible after an event. 
Brain imaging is recommended, and non-invasive imaging of 
the cervicocephalic vessels should be performed urgently and 
routinely as part of the evaluation. Carotid endarterectomy (CeA) 
is recommended for patients with severe (70 - 99%) ipsilateral 
stenosis, and the procedure should be performed as soon as 
possible after the last ischaemic event – ideally within 2 weeks – in 
centres with a peri-operative complication rate (all strokes and 
death) of less than 6%.
Survivors of a TiA or stroke have an increased risk of another stroke, 
which is a major source of increased mortality and morbidity. 
Secondary prevention strategies are aimed at reducing this risk. 
Stroke rehabilitation is a goal-orientated process that attempts to 
obtain maximum function in patients who have had strokes and 
who suffer from a combination of physical, cognitive and language 
disabilities.
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inhibitors; TCD – transcranial Doppler ultrasound; TiA – transient 
ischemic attack; tpA – recombinant tissue plasminogen activator.
1. Objective
There have been a number of new developments in stroke medicine 
since the publication of the first South African consensus document 
– the Stroke Therapy Clinical Guideline 2000.1 The benefits of 
thrombolytic therapy, stroke unit care, new imaging modalities 
and various other medical and surgical interventions in acute 
and preventive stroke care have improved. results of several well-
conducted studies now facilitate an evidence-based appraisal of 
new developments. numerous evidence-based national guidelines 
from countries in the developed and developing worlds have been 
published recently. The new developments have already begun 
changing stroke management in South Africa. The formulation of an 
updated South African consensus document was necessary, not only 
to educate South African health care professionals, students and the 
general public, but also to guide funding policies of South African 
private and public health care providers.
This guideline covers several aspects of stroke care, from primary 
prevention and acute management to rehabilitation and secondary 
prevention. Stroke care is multifaceted and complex. new evidence 
emerges every day. A compromise between comprehensiveness and 
readability needed to be reached, and therefore not all aspects of 
stroke care could be covered.
2. Methodology
2.1 Grading the level of evidence
Most national guideline recommendations either follow the appraisal 
system used by the American Heart Association, or the definitions 
of levels of evidence used by the european Stroke Organisation. The 
validity of both instruments has been well established. This guideline 
follows the european model.
2.2 The guideline development process
The guideline was compiled by the Stroke Guideline Writing 
Committee of the South African Stroke Society. This group consists 
of independent academic and private stroke neurologists and 
physicians. A broader stroke working group provided input to the 
guideline. possible conflicts are declared in the attached register of 
interests. Authors were nominated by consensus to write chapters of 
the Guideline. Submissions were first discussed in a meeting of the 
Stroke Guideline Writing Committee. The national Department of 
Health (Directorate Chronic Diseases, Disabilities and Geriatrics) 
participated in all aspects of the development of the guidelines.
A national consensus meeting of approximately 150 delegates 
was held on 15 - 17 July 2008; most were from the different regions 
in the state sector, and the Stroke Society was represented by 15 
members. The purpose of the meeting was to discuss the provisional 
draft of the guidelines and to obtain broad input and consensus 
on the guidelines from all relevant role players involved in the 
management and planning of stroke care in the country. The draft 
document was extensively edited by Associate professor Alan Bryer 
Evidence appraisal system
level A established as useful/predictive or not useful/
predictive for a diagnostic measure or established 
as effective, ineffective or harmful for a therapeutic 
intervention; requires at least one convincing class 
i study or at least two consistent, convincing class 
ii studies.
level B established as useful/predictive or not useful/
predictive for a diagnostic measure or established 
as effective, ineffective or harmful for a therapeutic 
intervention; requires at least one convincing class 
ii study or overwhelming class iii evidence.
level C established as useful/predictive or not useful/
predictive for a diagnostic measure or established 
as effective, ineffective or harmful for a therapeutic 
intervention; requires at least two class iii studies.
Good 
clinical 
practice 
(GCp)
recommended best practice based on the 
experience of the guideline development group. 
usually based on class iv evidence indicating large 
clinical uncertainty; such GCp points can be useful 
for health workers.
Evidence classification scheme for a therapeutic interven-
tion
Class i An adequately powered, prospective, randomised, 
controlled clinical trial with masked outcome 
assessment in a representative population; or 
an adequately powered systematic review of 
prospective, randomised, controlled clinical trials 
with masked outcome assessment in representative 
populations.
Class ii prospective matched-group cohort study in a 
representative population with masked outcome 
assessment; or a randomised controlled trial in a 
representative population that lacks one criterion for 
class i evidence.
Class iii All other controlled trials (including well-defined 
natural history controls or patients serving as own 
controls) in a representative population, where 
outcome assessment is independent of patient 
treatment.
Class iv evidence from uncontrolled studies, case series, case 
reports, or expert opinion.
Evidence classification scheme for a diagnostic measure
Class i A prospective study in a broad spectrum of 
persons with the suspected condition, using a 
‘gold standard’ for case definition, where the test 
is applied in a blinded evaluation, and enabling 
the assessment of appropriate tests of diagnostic 
accuracy.
Class ii A prospective study of a narrow spectrum of 
persons with the suspected condition, or a well-
designed retrospective study of a broad spectrum 
of persons with an established condition (by 
‘gold standard’) compared with a broad spectrum 
of controls, where test is applied in a blinded 
evaluation, and enabling the assessment of 
appropriate tests of diagnostic accuracy.
Class iii evidence provided by a retrospective study where 
either persons with the established condition or 
controls are of a narrow spectrum, and where 
test is applied in a blinded evaluation.
Class iv evidence from uncontrolled studies, case series, 
case reports, or expert opinion.
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to include inputs and comments from the consensus meeting as well 
as further submissions by various role players after reviewing the 
document. The final draft reflects a broad agreement on appropriate 
measures for current management of stroke in our unique health care 
environment.
2.3  stroke Writing Committee and Working 
Group members
The members of the Stroke Guidelines Writing Committee of the 
South African Stroke Society are: Chairman and editor: Associate 
professor Alan Bryer (Head of the Stroke unit, Division of neurology, 
Department of Medicine, Groote Schuur Hospital and university 
of Cape Town, chairman of the SA Stroke Society, and stroke 
portfolio incumbent of the SA Heart and Stroke Foundation); stroke 
Guideline Co-ordinator: Dr victoria pinkney-Atkinson (SASS); 
contributing members: Drs peter Haug (neurologist in private 
practice, Cape Town), Bonniface Cheyip (neurologist, Witbank 
Hospital, Mpumalanga Department of Health), Brent Tipping 
(geriatrician, Donald Gordon Medical Centre, Johannesburg), Hugh 
Staub (private practice rehabilitation neurologist, entabeni Hospital, 
Durban), Wienbren Duim (neurologist in private practice, little 
Company of Mary, pretoria), and Myles Connor (neurologist, Queen 
Margaret Hospital, Fife, Scotland and university of edinburgh; 
formerly of the university of the Witwatersrand). The stroke 
Guideline Working Group also included professor v u Fritz 
(emeritus professor of neurology, university of the Witwatersrand), 
professor A D Marais (Head of lipidology Division,Department of 
Medicine, Groote Schuur Hospital and university of Cape Town), 
Ms Sandhya Singh (Director: Chronic Diseases, Disabilities and 
Geriatrics, national Department of Health), Dr Marie Strydom 
(Deputy Director: Geriatrics, national Department of Health), 
Ms Anne Croasdale (Deputy Director: Chronic Diseases, national 
Department of Health), Mr Maluta Tshivhase (Deputy Director: 
Disabilities, national Department of Health), Ms elmarie van der 
Walt (Assistant Director: Geriatrics, national Department of Health) 
and Dr r Cornick (knowledge Translation unit, university of Cape 
Town).
2.4 Funding of the development and 
consensus process
Funding for the planning and convening of the Stroke Guideline 
Working Group meetings was covered by a grant from Boehringer 
ingelheim to the SASS. The grant was unconditional in that the 
donor made no input to the content of the guideline. The national 
Department of Health sponsored the consensus meeting held in 
2008.
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3. stroke in south Africa
3.1 stroke is a catastrophic illness in south 
Africa
Stroke was declared a catastrophic illness in South Africa on 26 
October 2007 at a historic ceremony that formed part of the Joint 
World Congress of Stroke.1 This declaration was endorsed by 
the three organising societies (the international Stroke Society, 
Mediterranean Stroke Society, and South African Stroke Foundation) 
as well as the World Stroke Federation. it was intended to focus both 
South African and world attention on the current burden and future 
impact of stroke on South Africans. Stroke is largely preventable by 
reducing vascular risk factors in the population (primary prevention), 
detecting and effectively managing individuals with stroke risk 
factors, and preventing stroke recurrence in those who have suffered 
a stroke through both lifestyle change and medical means (secondary 
prevention). notwithstanding the government’s achievements to 
date (in terms of the Tobacco products Control Amendment Act 
63 of 2008), a concerted effort is required by government, health 
professionals and individuals at risk to address issues relating to 
vascular risk, including lifestyle modification and treatment of 
medical conditions that confer increased stroke risk. Should such 
efforts fail, the burden of stroke in South Africa will increase and add 
to the burden of disease already facing the nation.2
3.2  stroke epidemiology in south Africa
3.2.1  The current burden of stroke in south Africa
The assessment of the burden of stroke in a population is based on 
the number of people who die from stroke (mortality), the number of 
people in the population at a given time who have survived a stroke 
(prevalence), and the number who have a stroke during a given year 
(incidence). We do not know the incidence of stroke in South Africa, 
but we do have data on stroke mortality and prevalence that highlight 
the impact of stroke on the population.3
3.2.2  stroke mortality
The South African national Burden of Disease Study estimated 
stroke mortality for the year 2000.2 The finding was that stroke was 
the third most common cause of death (6.5% of all deaths) after Hiv/
AiDS and ischaemic heart disease in South Africa (age-standardised 
mortality of stroke for both males and females in 2000 was 125 per 
100 000).4 Black women had the highest mortality rate owing to 
stroke (160 per 100 000), while mortality was lowest in white men 
(72 per 100 000). Deaths in the coloured and black population 
groups were double those in the white population. The risk of stroke 
increases with age, and it is therefore not surprising that there are 
more stroke deaths in older than in younger age groups in South 
Africa. According to statistics based on death registration, stroke is 
the most common cause of death of people over the age of 50 years.5 
More recent data from StatsSA report that there were just over 25 000 
deaths from stroke in 2007.6
3.2.3  stroke prevalence
The Southern African Stroke prevention initiative study (SASpi, 
2004) has provided the only community-based data on the prevalence 
of stroke in South Africa. The study assessed the prevalence of 
stroke (number of people in a given population with stroke at 
any given time) in the Agincourt demographic surveillance site 
in Mpumalanga. Stroke was about half as common in rural South 
Africa as in typical high-income populations of the world, but twice 
that found elsewhere in Africa. Specifically, the age-standardised 
prevalence of stroke was 290 per 100 000, and the crude prevalence 
was 300 per 100 000 (95% confidence interval (Ci) 250 - 357 per 100 
000).7 it would be ideal to use these findings to provide an estimate 
of the total number of people in South Africa who have had a stroke. 
unfortunately, there are so many unknown factors that influence 
this figure (such as population and urban-rural differences in stroke 
occurrence (incidence), stroke death (mortality) and the proportion 
of older and younger people) that an estimate based on SASpi 
findings would be extremely inaccurate. The SASpi study does, 
however, provide a very useful glimpse of the prevalence of stroke 
in rural South Africa. Stroke prevalence in urban areas is probably 
higher than in rural areas because people are probably exposed to 
more lifestyle risk factors.
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3.2.4  stroke-related disability
The SASpi study compared the prevalence of stroke survivors who 
required help with at least one activity of daily living (a marker of 
disability) with similar figures from Tanzania and new Zealand. 
There were far more disabled stroke survivors in rural South Africa 
than in Tanzania, and about the same number as in new Zealand, 
which has a high-income population with (most likely) a higher 
incidence of stroke than South Africa.7 it is not clear why there are 
so many disabled stroke survivors in South Africa. This finding may 
be the result of inadequate rehabilitation services, but may also be 
because minor strokes are not often diagnosed or reflect differences 
between the research studies in the two countries. Other explanations 
include: unwillingness by patients to receive rehabilitation or to 
complete a rehabilitation programme owing to fear of being denied 
or withdrawn from a disability grant if fully rehabilitated; a lack of 
transport to attend outpatient rehabilitation sessions for patients 
travelling long distances to the nearest clinic or hospital; and delays 
in management of acute stroke.
The South African national Burden of Disease Study estimated 
national disability-adjusted life years (DAlys) and years of life lost 
due to premature death.2 These are rather complex measures that were 
first used by the WHO and the Global Burden of Disease Study to 
compare the level of disability and the years of life that are potentially 
lost as a result of a disease across populations and countries. Despite 
the high prevalence of Hiv/AiDS and other infections which cause 
disability, as well as disability due to violence and trauma in South 
Africa, stroke is the 8th most significant cause of years of life lost due 
to illness, and the 9th most important cause of disability.
3.3  Risk factors for stroke
risk factors for stroke may be modifiable (i.e. risk that may be avoided 
or reduced) or non-modifiable (i.e. factors such as increasing age and 
male gender). A more detailed account of what is known about these 
risk factors in South Africa is available in a recent Medical research 
Council (MrC) technical report.8
The South African Comparative risk Assessment Collaborating 
Group (2007) recently estimated the contribution of 8 risk factors 
to stroke.9 These are listed in order of their contribution (with 
attributable fraction in brackets) from highest to lowest:
•   high blood pressure (52%)
•   tobacco (24%)
•   excessive body weight (18%)
•   high cholesterol (15%)
•   physical inactivity (12%)
•   low fruit and vegetable intake (12%)
•   diabetes (8%)
•   alcohol (8%).
These risk factors frequently coexist.
The prevalence of risk factors for stroke varies across the population 
groups in South Africa, as found in over 9 000 people over the age 
of 30 years without stroke attending general practices, in the South 
African Stroke risk in General practice study.10 Hypertension was 
the most common risk factor in all population groups, and was found 
in more than half of people attending general practices (55%), while 
elevated cholesterol was common in the white (37%) but not the 
black (5%) population groups, while diabetes was most common in 
the indian/Asian population groups (24%).
3.4  Types of stroke
There are two main types of stroke:
•    ischaemic stroke (85%), caused by an embolus or thrombosis
•    cerebral haemorrhage (15%), caused by the rupture of a cerebral 
vessel with bleeding into the brain.
There are also several subtypes of each of these conditions. The 
relative proportion of the types of stroke varies across populations, 
probably because of differences in their risk factor profiles, e.g. in 
populations with a high prevalence of hypertension but low levels 
of other risk factors, cerebral haemorrhage may be relatively more 
common than in populations with a greater mix of lifestyle risk 
factors.8,11
3.5  Prevalence of stroke types in south Africa
Stroke in South Africa reflects the prevalence and combination of 
risk factors found in the different population groups of the country. 
For example, in a recent hospital-based stroke series, cerebral 
haemorrhage (mainly the result of hypertension) was found twice 
as often in black (28%) as in white (15%) stroke patients,11 which 
is typical of the findings from other South African and African 
hospital-based stroke studies that have found cerebral haemorrhage 
in around a third of black stroke patients.9
extracranial atherosclerotic disease, a common cause of ischaemic 
stroke in white and indian/Asian stroke patients, is uncommon in 
black stroke patients.12,13 Although the incidence of stroke increases 
with increasing age in the black South African population as in 
other population groups, some studies have found that the incidence 
of stroke in younger age groups (35 - 54 years) is higher than that 
found in other populations.3 Furthermore, stroke management – 
particularly in young South Africans – is complicated by the high 
prevalence of human immunodeficiency virus (Hiv). Hiv infection 
may cause stroke through opportunistic infections, secondary to 
involvement of the heart by Hiv, possibly by changes in coagulation 
factors, and through direct or indirect damage to blood vessels (Hiv-
associated vasculopathy).10,14-16
3.6  The cost of stroke
Stroke carries with it an inherent cost to the affected individual, their 
family and carers, the community and, more broadly, the health 
services and country. unfortunately, there is almost no information 
available to accurately guide estimation of these costs.17
3.7  The future of stroke in south Africa
Much of the population of South Africa is undergoing a rapid 
epidemiological transition with increased exposure to, and 
development of, stroke risk factors, together with ageing (of the 
population);10,18,19 this will inevitably result in an increase in the 
burden of stroke.
Recommendations
•    educational programmes to increase awareness of stroke at the 
population level (Class II, level B)
•    educational programmes to increase stroke awareness among 
professionals (paramedics, emergency physicians) (Class II, level 
B).
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4.  The stroke unit model of care
4.1  Organisation of stroke services and 
benefits of stroke unit care
•    The most effective care for stroke patients is provided in a 
geographically defined ward area where care is provided by a 
specialised, experienced stroke team.1-5
•    The structure of stroke unit care varies between facilities, but 
all provide care according to protocols, and have regular team 
meetings and access to ongoing education.
•    Treatment in a stroke unit compared with treatment in a routine 
clinical setting has been shown in studies to reduce mortality as 
well as reduce the likelihood of dependency after stroke.2
•    Stroke unit care as provided in routine clinical practice has also 
been shown to reduce case fatality.4,5
•    All types of stroke patients benefit from treatment and rehabilitation 
in stroke units: males and females, young and elderly stroke 
patients, and patients with mild, moderate and severe strokes.
•    Stroke unit care incorporates many elements working together, 
and it is difficult to identify any specific factor responsible for 
better outcome.
4.2 Defining a stroke unit
•    A stroke unit is a dedicated and geographically defined part of a 
hospital that takes care of stroke patients in both the acute and 
immediate post-acute phase.
•    it has specialised staff with a co-ordinated multidisciplinary expert 
approach to treatment and care.
•    it comprises core disciplines: medical, nursing, physiotherapy, 
occupational therapy, speech and language therapy, and social 
work.1
4.3 Essential components of a stroke unit
•    Comprehensive assessment of medical problems, impairments 
and disabilities by specialist staff (i.e. professionals interested and 
trained in stroke care).
•    established pathways and management protocols for acute and 
post-acute management of stroke (including pre-hospital and 
emergency unit management of stroke) with careful attention to 
active management of physiological abnormalities to maintain 
homeostasis.
•    Care co-ordinated by a multi-disciplinary team (MDT) with 
regular scheduled ward rounds attended by the full MDT to 
discuss management strategy for each patient. The co-ordinated 
MDT should ideally include a stroke physician, nursing staff, 
occupational therapist, physiotherapist, speech pathologist, 
dietician, social worker and, where possible, a psychologist.
•    Should ideally be in a designated space within hospital, with 
designated stroke unit beds.
•    early mobilisation.
•    Skilled nursing care.
•    early initiation of rehabilitation plan involving the carers.
•    Scheduled patient and family education concerning management, 
rehabilitation programme, causes of stroke, secondary prevention 
and community resources.
•    early assessment and planning of discharge needs and planning 
for home-based care with either family member, care-giver or 
community rehabilitation worker.
•    initiation of secondary prevention strategies.
•    All staff must undertake ongoing training and education in stroke 
management.
Recommendations
•    All stroke patients should be treated in a stroke unit (Class I, 
level A).
•    Health care systems must ensure that acute stroke patients can 
access high-technology medical and surgical stroke care when 
required (Class III, level B).
•    The development of clinical networks, including telemedicine, is 
recommended to expand the access to high-technology specialist 
stroke care (Class II, level B).
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of Health stroke initiative in order to provide a service with defined 
protocols for stroke care. established units such as those in the 
public sector of the Western Cape could serve as a model for the 
re-organisation of existing resources to provide more effective stroke 
care without necessarily incurring additional cost. The stroke unit 
model at G F Jooste Hospital has demonstrated efficacy in reducing 
mortality after implementation.1 local protocols should be developed 
according to available resources to guide the delivery of stroke 
services at a particular health care facility.
Stroke services should be organised so as to recognise the special 
medical, social and rehabilitative needs of stroke patients in specific 
sub-groups (e.g. paediatric and young adult patients) and be 
tailored to accommodate the cultural and linguistic diversity of the 
population. An effective stroke service requires the establishment of 
a seamless network consisting of acute stroke units, post-acute care 
and rehabilitation, as well as further care in the community. problems 
of limited infrastructure and shortage of staff need to be addressed at 
national, provincial and district levels.
5.3  Proposals for stroke care within the sA 
health care system
The public health care system is stratified into different levels of care, 
and the following proposals for stroke care are based on the current 
guidelines for stroke care applied to the categories of health facilities 
defined by the national Department of Health (October 2006.)
5.3.1  Facilities providing predominantly ambulatory 
care
The aspects of stroke care listed below should be available at 
predominantly ambulatory care facilities. Medical and nursing staff, 
health promoters and community health workers at these facilities 
should have specific training for:
•    awareness of risk factors for stroke
•    recognition of symptoms and signs of stroke and transient 
ischaemic attack (TiA)
•    implementation of primary preventive measures to reduce stroke 
incidence
•    implementation of secondary preventative measures to reduce 
incidence of stroke after TiA or stroke
•    established protocols of referral for selected patients to higher level 
of care according to defined criteria.
5.3.2  Facilities providing inpatient services
level 3 hospital
A facility that provides specialist and sub-specialist care as defined 
for level 3 services. recommendations for a level 3 facility are a 
comprehensive stroke unit and service requirements as follows:
•    all essential components of a stroke unit (as defined in paragraph 
4.2)
•    staffing to include stroke specialists (specialist physicians or 
neurologists trained in stroke care, neurosurgical service) and full 
multidisciplinary team (all disciplines)
•    24-hour comprehensive laboratory service including haematology 
with clotting profile
•    full neuroradiology service (CT, Mri with software for diffusion-
weighted and MrA images, angiography, duplex Doppler carotid 
sonography)
•    catheter laboratory facility with stroke interventionist available for 
endovascular procedures
•    focused vascular surgery available (carotid, coronary, peripheral)
•    full cardiac service including transthoracic echocardiogram and 
trans-oesophageal echocardiography
•    protocols for:
•    intravenous and intra-arterial interventional (thrombolysis) 
management of acute ischaemic stroke with supportive 
management in stroke unit as per protocol with high-care 
monitoring available for first 24 - 48 hours
•    investigation and management of stroke in the young patient
•    investigation and management (including neurosurgical) of 
intracranial haemorrhage.
•    in a resource-constrained health care environment, examples of 
patients likely to be referred to a level 3 comprehensive stroke 
unit would be younger stroke patients with unknown cause for 
stroke; patients with symptom onset to predicted time of arrival at 
a level 3 hospital to be less than 3.5 hours (i.e. patient who could 
benefit from thrombolysis – neurosurgical and haematological 
backup required); patients with suspected cardio-embolic stroke 
(e.g. cardiac causes not due to atrial fibrillation and not previously 
investigated for cardiac disease); patients with TiAs (especially 
crescendo TiAs) presenting within 48 hours (urgent investigation 
to prevent stroke); and patients who require urgent CT scan if 
unavailable at the level 2 or level 1 hospital.
ideally, every patient with stroke should have a CT scan as part 
of the management, but in reality this not always feasible because 
of logistic and resource constraints in many parts of the country. 
However, under certain circumstances, patients may well require 
referral to another centre for an urgent CT or Mri brain scan.
Indications for URGENT CT scan include: (i) depressed level 
of consciousness for which the cause is uncertain; (ii) suspected 
subarachnoid haemorrhage or cerebellar haematoma; (iii) if the 
diagnosis is in doubt – to exclude treatable causes e.g. subdural 
haematoma, space-occupying lesion or other mimics of stroke; (iv) 
if anticoagulants (e.g. patient in atrial fibrillation) or thrombolytic 
therapy are planned – for immediate detection of intracerebral 
haematoma or haemorrhagic infarct; (v) worsening neurological 
deficits; (vi) history or clinical findings suggestive of trauma; and 
(vii) ongoing seizures.
level 2 hospital (regional)
This is a facility that provides care requiring the intervention of 
specialists as well as general practitioner services. recommendations 
for a level 2 stroke unit are: 
•    all essential components of a stroke unit (as defined in paragraph 
4.3)
•    internal medicine specialist cover trained in stroke care
•    CT scan facility on site with radiology cover to interpret scans
•    essential investigations available: electrocardiogram (eCG), chest 
X-ray, basic laboratory service for FBC, erythrocyte sedimentation 
rate (eSr), international normalised ratio (inr), syphilis testing 
(rpr and vDrl), blood sugar, urea and electrolytes. level 2 
hospitals should have easy access to echocardiography.
•    Stroke patients who require investigation and management by a 
team led by a specialist physician will probably be managed at a 
level 2 unit. examples of patients who should ideally be managed 
in a level 2 unit include: patients with cardio-embolic stroke 
where the cardiac cause is known and the local physician assesses 
the need and timing of anticoagulation; stroke patients with no 
cause or obvious risk factors for stroke that can be investigated on 
site; and stroke patients with depressed level of consciousness for 
which the cause is confirmed on CT scan and who do not require 
neurosurgical or other level 3 intervention.
•    Certain level 2 regional hospitals (e.g. those with 24-hour CT 
scan on site and physicians able to interpret acute stroke scan, 
24-hour laboratory service, and neurosurgical cover) could develop 
protocols for intravenous thrombolysis for acute ischaemic stroke.
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•    level 2 stroke units should have a protocol for transfer of selected 
stroke patients to a level 3 facility. reasons for referral may 
include:
•    selected patients who may benefit from thrombolysis and can 
reach a level 3 hospital within 3 hours of onset of symptoms of 
stroke.
•    where urgent CT scan is required and is not currently available 
at the level 2 hospital (see indications above). Should CT 
on such patients reveal a subarachnoid haemorrhage or any 
lesion (including a lobar haemorrhage or cerebellar infarct or 
haemorrhage) with significant mass effect, then referral of the 
patients to neurosurgery is indicated before they can return to 
the level 2 hospital.
•    patients with CT scans done at level 2 who show a subarachnoid 
haemorrhage or any other lesion (including a lobar haemorrhage 
or cerebellar infarct or haemorrhage) with significant mass effect 
on scan that requires neurosurgical intervention. Decompression 
may also be considered for the malignant middle cerebral artery 
syndrome.
•    stroke in young patients for which no cause can be found.
•    suspected cardio-embolic stroke (not associated with atrial 
fibrillation and not previously investigated for cardiac disease)
•    patients with TiA onset within 48 hours of presentation require 
urgent vascular assessment (and carotid Doppler or vascular 
imaging not available at level 2)
•    when a physician at level 2 facility requests further investigations 
not available at level 2 to determine cause of stroke (e.g. 
stroke due to a suspected arterial dissection)where there are 
large distances between level 3 and level 2 hospitals, the use 
of telemedicine or other telecommunication links should be 
explored
•    all level 2 hospitals that do not meet the requirements listed 
above should have a level 1 stroke unit or service.
level 1 hospital
A facility at which a range of outpatient and inpatient facilities 
are offered, where patients have conditions that can be managed 
by a medical officer or a team led by a family physician. level 1 
hospitals typically do not provide on-site cranial CT scanning. The 
recommendations for level 1 stroke unit or service are:
•    minimum staffing requirements: medical, nursing and physiotherapy 
personnel trained in stroke care
•    comprehensive assessment of medical problems, impairments and 
disabilities
•    established pathways and protocols for acute and post-acute 
management of stroke with careful attention to active management 
of physiological abnormalities to maintain homeostasis
•    early initiation of rehabilitation plan involving the carers
•    scheduled patient and family education about management, 
rehabilitation programme, causes of stroke, secondary prevention 
and available community resources
•    early assessment and planning of discharge needs
•    initiation of secondary prevention strategies
•    ongoing staff training and education in stroke care
•    protocol for referral and transfer of selected stroke patients to a 
level 2 or 3 facility: Where there are large distances between level 
1 and level 2 or level 3 hospitals, the use of telemedicine or other 
telecommunication links should be explored.
Reasons for referral may include: (i) selected patients who may 
benefit from thrombolysis and can reach a level 3 hospital within 3 
hours – refer direct to level 3; (ii) where urgent CT scan is required 
(see above); (iii) patients with suspected cardio-embolic stroke; (iv) 
stroke patients with depressed level of consciousness; (v) all stroke 
patients with suspected intra-cranial haemorrhage; (vi) younger 
stroke patients with unknown cause of stroke in whom family 
physician at level 1 requests further investigations not available at 
level 1 to determine cause of stroke; (vii) patients with suspected 
posterior fossa haemorrhage or infarct who may require surgical 
decompression; and (viii) patients with TiA onset within 48 hours 
of presentation.
Reference
6. Primary stroke prevention
primary preventive measures reduce stroke incidence and should be 
universally available and actively promoted at all levels of health care 
in South Africa.1
6.1 lifestyle characteristics identified as a risk 
factors for stroke
6.1.1 smoking
•    Cigarette smoke is an independent risk factor for ischaemic stroke 
in men and women.13
•    Smoking approximately doubles the risk of ischaemic stroke 
compared with non-smokers.13
•    Smoking cessation reduces risk by 50% over 1 year and continues 
to decline, returning to baseline after 5 years.14
6.1.2 Body weight and body fat distribution
•    increased body weight status defined by a BMi (kg/m²) >25 
and increased abdominal fat (central obesity as measured by 
increased waist circumference >94 cm in men and >80 cm in 
women) has been associated with stroke risk in white people 
of european origin regardless of where they live in the world. 
These measurements vary for ethnic groups with lower waist 
circumference measurements applicable to South Asians, Japanese 
and people of Chinese decent. Specific data for Sub-Saharan 
Africans are currently not available. 2-5
•    Weight reduction is recommended and may lower blood pressure, 
thereby reducing risk of stroke.6
6.1.3 Physical activity
exercise has beneficial effects on several important stroke risk factors 
and is associated with a reduction in stroke risk.7 
6.1.4 Nutrition
•    Diets rich in vegetables and fruits and with reduced sodium and 
increased potassium reduce stroke risk.8,9
•    Specific diets lower blood pressure; these include the DASH diet 
(emphasis on vegetables and fruit, low-fat dairy products and a 
reduction in saturated and total fat) and diets low in sodium and 
rich in potassium.10-12
6.1.5 Alcohol
light-to-moderate consumption (≤2 drinks per day for men and ≤1 
drink per day for women) has been associated with reduced stroke 
risk. Heavier alcohol consumption (>60 ml/day) increases the risk of 
both ischaemic (rr 1.69) and haemorrhagic stroke (rr 2.18).15
Recommendations
•    primary preventive measures reduce stroke incidence (Class III, 
level A).
1.    de villiers l, kalula SZ, Burch vC. Does multidisciplinary stroke care improve outcome in a secondary-
level hospital in South Africa. int J Stroke 2009;4(2):89-93.
759november 2010, vol. 100, no. 11  sAMJ
GUIDElINE
•    Abstention from smoking or smoking cessation (Class III, level 
B).
•    Weight reduction is recommended for those individuals with a 
BMi >25kg/m2 (Class III, level B).
•    regular physical activity ≥30 minutes of moderate-intensity 
exercise daily (Class III, level B). 
•    A diet low in sodium and rich in vegetables, fruits, lower total fat 
and saturated fat intake (Class III, level B).
•    Men should consume ≤2 and non-pregnant women ≤1 units (12 
ml) alcohol/day, and heavy use of alcohol is discouraged (Class 
III, level B).
6.2 Medical conditions identified as risk 
factors for stroke
6.2.1 Hypertension
•    High blood pressure (≥130/85 mmHg) is the most important and 
prevalent modifiable risk factor for stroke.
•    Significant reduction of stroke incidence occurs with a decrease in 
blood pressure.16,17
6.2.2 Diabetes mellitus
•    Diabetes is an independent risk factor for ischaemic stroke.
•    in patients with diabetes mellitus, tight blood pressure control and 
therapy with a statin reduces the risk of stroke.18,19
•    Treatment of hypertension should where possible include an 
angiotensin-converting enzyme inhibitor or angiotensin receptor 
antagonist (usually in combination with a diuretic).17
•    Clear evidence showing that risk of stroke is reduced by tight 
glycaemic control is lacking.
6.2.3 Dyslipidaemia
•    The assessment of dyslipidaemia is best done in a fasting state to 
evaluate triglyceride, total cholesterol, HDl cholesterol and lDl 
cholesterol.
•    Although the role of dyslipidaemia in ischaemic stroke causation, 
unlike its role in coronary artery disease, is not clear from 
epidemiological studies, it is associated with atherosclerosis – an 
important cause of stroke. Moreover, following an ischaemic 
stroke, lipid-lowering therapy is clearly beneficial.
•    A thorough clinical assessment includes lifestyle and family 
history as well as a search for secondary causes that should be 
identified and addressed (for hypercholesterolaemia, conditions 
such as hypothyroidism, nephrotic syndrome and a fat-rich 
diet need to be considered; for hypertriglyceridaemia, consider 
diabetes, alcohol abuse, renal failure and hypothyroidism. Some 
medications may also affect the lipid profile adversely, though few 
do so profoundly.
•    Diet influences plasma concentrations of cholesterol through 
the intake of cholesterol and saturated fat. Triglyceride intake in 
general should be limited in hypertriglyceridaemias. Statins are 
the drugs of choice in hypercholesterolaemias, but some mixed 
hyperlipidaemias and almost all hypertriglyceridaemias respond 
well to diet and fibrates.
•    in high-risk patients with vascular disease and total cholesterol 
>3.5 mmol/l, taking a statin is associated with reduced ischaemic 
stroke (and myocardial infarction) rates.19
•    For primary prevention, drug treatment is advised for persons with 
monogenic disorders and those with a high global risk score.20 
This measure takes into account age, gender, total cholesterol (or 
lDlC), HDl cholesterol, smoking and blood pressure. Owing 
to the high risk for cardiovascular disease in diabetes mellitus, 
this has become a secondary prevention equivalent. Manifest 
atherosclerosis justifies treatment of the dyslipidaemia and is 
considered secondary prevention.
•    Severe dyslipidaemia should be evaluated by a specialist physician 
to diagnose the monogenic disorders and consider less common 
secondary causes (referral criteria include: total cholesterol >7.5, 
lDlC >5, HDlC >2.5 or triglyceride >5 mmol/l. urgent attention 
and referral is necessary for hypertriglyceridaemia(>15 mmol/l), 
low cholesterol (<1.5 mmol/l) or low HDl cholesterol (<0.8 
mmol/l). The presence of tendon or cutaneous xanthomas should 
also be considered as reasons for referral, or significant adverse 
effects with lipid-modifying medication.
6.2.4 Cardiac disease
•    patients with mechanical heart valves, and atrial fibrillation 
with valvular heart disease, are at risk of future embolic events 
and should be anticoagulated, provided there are no clinically 
significant contraindications to anticoagulants.21,22
•    Antiplatelet therapies reduce the risk of stroke in patients with 
atrial fibrillation but are less effective than anticoagulation.23
•    The CHADS2 scoring system identifies patients with atrial 
fibrillation for primary stroke prevention reliably and allows 
selection of appropriate anticoagulant therapy (Table i).24,25
Recommendations
•    Hypertension should be managed with lifestyle modification and 
pharmacotherapy (choice of regimen individualised and should 
follow SA Hypertension Society guidelines17) (Class I, level A).
•    Blood glucose should be checked regularly. Diabetes should 
be managed with lifestyle modification and individualised 
pharmacological therapy (Class IV, level C). in diabetic patients, 
high blood pressure should be managed intensively (Class i, level 
A) aiming for levels <130/80 mmHg (Class IV, level C). Where 
possible, treatment should include an angiotensin-converting 
enzyme inhibitor or angiotensin receptor antagonist (Class I, 
level A).
•    For primary prevention, patients with monogenic disorders 
(evidenced by severe dyslipidaemia) or with type 2 diabetes or type 
1 diabetes with micro-albuminuria, or those with a high global 
risk score, require dietary measures and lipid modifying treatment 
(Class I, level A).
•    Considering patient preferences, bleeding risk and access to reliable 
inr monitoring, the following patients should be considered for 
anticoagulation therapy with warfarin: patients with mechanical 
heart valves (target inr 2.5 - 3.5), patients with valvular heart 
disease and atrial fibrillation, and patients with a CHADS2 score 
indicating moderate or greater risk of stroke (target inr 2.0 - 3.0) 
(Class I, level A). lower-risk patients with atrial fibrillation or 
those in whom oral anticoagulation is clinically contraindicated 
should be considered for aspirin therapy (75 - 300 mg/day).
6.3 Other primary stroke prevention 
interventions
6.3.1 Aspirin for primary stroke prevention
low-risk subjects
•    Six large randomised trials have evaluated the benefits of aspirin 
for the primary prevention of  Cv events in men and women (47 
293 on aspirin, 45 580 controls) with a mean age of 64.4 years.26-31 
Aspirin reduced coronary events and Cv events, but not stroke, 
Cv mortality and all-cause mortality.32
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•    no data are currently available on the use of other antiplatelet 
agents in primary prevention in low-risk subjects.
subjects with vascular risk factors
•    A systematic review of randomised studies comparing 
antithrombotic agents with placebo in patients with elevated Bp 
and no prior Cv disease showed that aspirin did not reduce stroke 
or total cardiovascular events.33 
•    patients with atherosclerotic arterial disease have an increased risk 
of myocardial infarction, stroke and cardiovascular death. Aspirin 
reduces myocardial infarction in patients with asymptomatic 
carotid artery disease, and reduces stroke after carotid artery 
surgery.34,35
6.3.2 Vitamins for primary stroke prevention
•    A low intake of vitamin D is associated with increased risk of 
stroke, but supplements of calcium plus vitamin D do not reduce 
the risk of stroke.36,37
•    Supplements of tocopherol and beta carotene do not reduce 
stroke.38 A meta-analysis of trials with vitamin e supplementation 
found that it might increase mortality when used at high doses 
(>400 iu/d).39
•    High homocysteine levels are associated with increased stroke risk. 
However, a recent Cochrane systematic review did not find any 
evidence to suggest that dietary supplementation with folic acid or 
other B vitamins reduced stroke risk.40,41
•    Folic acid and vitamin B12 supplementation (with or without the 
addition of vitamin B6) does not reduce the risk of major Cv 
events in patients with established vascular disease.42,43
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CHADS2 
score* risk level Stroke rate
Treatment 
recommendations
0 low 1.0%/yr
Aspirin (75 - 325 
mg/d)
1 low-
moderate
1.5%/yr Warfarin inr 2 - 3 
or aspirin (75 mg - 
325 mg/d)
2 Moderate 2.5%/yr Warfarin inr 
2 - 3†
3 High 5.0%/yr Warfarin inr 2 - 3
4 very high >7%/yr Warfarin inr 2 - 3 
Congestive heart failure, hypertension, age >75 yrs or diabetes = 1 
point each.
*The CHADS2 scheme should be applied for primary prevention.
†Consider patient preferences, bleeding risk and access to good 
inr monitoring. For those with a CHADS2 score = 1, the number 
needed to treat to prevent 1 stroke over 1 yr with warfarin is ≈100; 
excellent anticoagulation control is essential to achieve this benefit.
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7.  Pre-hospital stroke management
7.1  Public awareness and education
•    Successful care of the stroke victim begins with recognition by the 
public and health professionals that stroke is an emergency, like 
myocardial infarction.
•    Avoiding delay should be the major aim of the prehospital phase 
of acute stroke care.
•    Most stroke patients do not receive adequate therapy because they 
do not reach hospital soon enough.1
•    Delays during acute stroke management have been identified at 
different levels: 2
•    at the population level, owing to failure to recognise the 
symptoms of stroke and contact emergency medical services 
(eMS)
•    at the level of eMS and emergency physicians, owing to a failure 
to prioritise transport of stroke patients
•    at the hospital level, owing to delays in neuro-imaging and 
inefficient in-hospital care, including a lack of protocol-driven 
acute stroke care.
•    The interval from symptom onset to first call for medical help is 
the predominant part of prehospital delay.3-6 Major reasons for 
delayed contact include lack of awareness of stroke symptoms and 
recognition of their severity, but also denial of the disease and the 
hope that symptoms will resolve.
•    The foregoing suggests that educating the population to recognise 
stroke symptoms, and changing people’s attitudes to acute stroke, 
may reduce the delay from stroke onset to eMS involvement.
•    education should also be directed to paramedics and emergency 
department staff to improve the accuracy of stroke identification 
and speed up transfer to hospital.7 education of paramedics 
increases stroke knowledge and clinical and communication skills, 
and decreases prehospital delays.8
7.2 Organisation of ambulance service
•    immediately stroke symptoms are suspected, patients or their 
proxies should call eMS.
•    emergency ambulance services should be organised to enable 
prompt response with the aim of transporting suspected stroke 
patients without delay to the emergency room of the nearest 
hospital (preferably with a stroke unit) that can provide organised 
acute stroke care.9,10
•    patients with onset of stroke symptoms within 3 hours should be 
given priority in evaluation and transportation to a level 2 or level 
3 hospital where protocols for thrombolytic therapy are available.
•    Doctors who receive a call or consultation from a patient 
with suspected stroke should recommend or arrange immediate 
transportation to the nearest hospital providing organised acute 
stroke care and ultra-early treatment.
•    patients with suspected subarachnoid haemorrhage should be 
referred urgently to a hospital with neurosurgical facilities.
•    The emergency numbers used by the community should be user-
friendly and easily accessible. every ambulance service should 
be provided with information regarding hospitals that are well 
equipped to care for stroke victims in their vicinity.
7.3  Pre-hospital diagnosis of stroke
•    inaccurate initial diagnosis by professional groups represents a 
major problem.11,12
•    eMS should have validated algorithm of questions to diagnose 
stroke during the phone interview.
•    There should be in-house training of all paramedics, particularly 
pertaining to diagnosis and pre-hospital care of stroke patients.
•    paramedics should be able to recognise symptoms and signs of 
stroke and diagnose stroke using simple instruments such as the 
Face-Arm-Speech-Test.13
7.4  Pre-hospital care
protocols should be used to guide pre-hospital stroke care. These 
concern maintaining physiological homeostasis and management 
of early complications or co-morbidities of stroke, such as impaired 
consciousness, seizures, vomiting or haemodynamic instability. 
General measures may include:
•    Assess airway, breathing, circulation and disability (though 
assessment of disability should not delay transfer to hospital).
•    record history of event, including time of onset, signs and 
symptoms, and previous medical, drug and social history. This 
information should be obtained from patient and/or informant; 
the informant should be encouraged to accompany the patient. All 
medication should be brought with the patient.
•    Alert the nearest stroke unit if the patient is potentially suitable 
for thrombolysis.
•    patients should receive nil by mouth.
•    Maintain airway; patients may require oxygen to maintain 
saturation over 95%.
•    Blood glucose should be measured if possible, and hypoglycaemia 
should be treated if present with intravenous glucose solution.
•    Maintain haemodynamic stability: actively manage hypotension by 
giving saline and/or raising the foot of the trolley.
Recommendations
•    educational programmes to increase public awareness of stroke 
(Class II, level B).
•    educational programmes to increase stroke awareness among 
health care professionals (paramedics and emergency physicians) 
(Class II, level B).
•    immediate eMS contact and dispatch to the nearest hospital 
(preferably with a stroke unit) that can provide organised acute 
stroke care for patients with suspected stroke (Class II, level B).
•    priority transport with advance notification to the receiving 
hospital for patients with onset of stroke symptoms within 3 hours 
(Class III, level B).
•    Ambulance personnel should be trained to recognise stroke using 
simple instruments such as the FAST test (Class IV, GCP).
•    During transport of stroke patients to hospital, paramedics 
should maintain physiological homeostasis and manage early 
complications or co-morbidities of stroke, according to protocol 
(Class IV, GCP).
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8. Management of acute ischaemic 
stroke
8.1 Urgent management
Acute stroke/TiA should be treated as a medical emergency and 
evaluated with minimum delay, regardless of severity of deficits. 
in-hospital delays and time loss are a problem, especially for patients 
who are potential candidates for thrombolysis. ideally, such patients 
should be evaluated and have a CT brain scan within 30 minutes of 
arrival in the emergency unit. emergency units must create efficient 
pathways and processes to identify and evaluate suspected stroke 
patients, with rapid triage.
8.2 Clinical assessment
initial evaluation of a suspected stroke patient entails checking 
vital signs and stabilisation of the patient, followed by assessment 
of neurological deficit and co-morbidities. Goals of this assessment 
include:
•    determining whether patient has had a stroke
•    identifying whether or not the patient is a suitable candidate for 
emergency interventional therapy with agents such as tpA
•    excluding stroke mimics (i.e. other conditions with stroke-like 
symptoms)
•    identifying other conditions that require immediate intervention 
(e.g. hypoglycaemia – urgent blood glucose assessment and treat 
if hypoglycaemic)
•    determining potential causes of the stroke for early secondary 
prevention.
The cornerstone of the clinical assessment remains the history, 
general examination and neurological examination.
8.2.1 Medical history
•    important information to obtain includes:
•    time of onset of symptoms of stroke (defined as when patient was 
last awake and symptom-free or known to be asymptomatic)
•    past medical history, particularly history of cardiac disease, 
peripheral vascular disease, diabetes and hypertension
•    risk factors for atherosclerosis
•    history of drug abuse, trauma, pregnancy, migraine, seizures, 
infection.
8.2.2  Clinical examination
General examination
•    Assessment of vital signs, that should also include blood sugar, 
pulse oximetry, and body temperature.
•    examination of head and neck for signs of trauma, seizure activity 
(contusions and tongue lacerations), carotid bruits.
•    Cardiac and vascular examination.
•    respiratory, abdominal and skin examination may reveal 
co-morbidities that may be associated with stroke risk or cause.
Neurological examination
•    Should be brief but thorough.
•    it is enhanced by use of a formal stroke score or scale, 
such as the niH Stroke Scale (niHSS).1 The niHSS provides 
important information about the severity of stroke and prognostic 
information, and the score may influence decisions about acute 
treatment. This scale can be performed with a reasonable degree of 
accuracy by practitioners in a broad range of specialties.2
•    The mrS (modified rankin score) is a simple disability score often 
used to measure stroke outcome.3
8.3 Diagnostic tests
Several tests should be done routinely on patients with suspected 
ischaemic stroke to identify conditions that may cause or mimic 
stroke or that may influence therapeutic options.
8.3.1 All patients
•    blood glucose
•    full blood count
•    urea, creatinine, electrolytes
•    eSr or Crp
•    eCG
•    chest X-ray
•    oxygen saturation.
8.3.2 Investigations that may be required on selected 
patients
•    inr if patient suspected or known to be on warfarin
•    fasting serum lipids
•    serological test for syphilis (rpr or vDrl)
•    lumbar puncture
•    echocardiogram: transthoracic or transoesophageal
•    24-hour cardiac Holter
•    full hypercoagulation screen
•    anticardiolipin antibody (both igG and igM), thrombophilia 
screen
•    collagen screen
•    hepatic function tests
•    toxicology screen
•    Mri/MrA scan (diffusion and perfusion sequences), Mr 
venogram
•    CT angiogram
•    cerebral angiography
•    carotid duplex Doppler ultrasonography of neck.
FAsT test
F –Facial movements: Ask the patient to smile or show teeth. look 
for new asymmetry.
A – Arm movements: Ask the patient to lift both arms together and 
hold. Does one arm drift or drop?
s – speech: if the patient attempts conversation, look for speech 
disturbance.
T – Time: Act quickly and document time of onset of stroke 
symptoms.
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8.3.3 Brain imaging
•    Brain imaging distinguishes ischaemic stroke from intracranial 
haemorrhage (haemorrhage v. infarct cannot be reliably 
predicted on clinical grounds, and management differs) and 
identifies other stroke mimics (e.g. neoplasm).
•    non-contrast CT scan of the brain distinguishes reliably between 
haemorrhagic and ischaemic stroke and is the most cost-effective 
strategy for imaging acute stroke patients.4 non-haemorrhagic 
infarcts (ischaemic strokes) may not be apparent on CT scan 
within the first 6 hours of onset.
•    ideally, all stroke patients should have CT brain scan to accurately 
determine accurately the type of stroke and the anatomy of the 
stroke (an important clue to aetiology). in reality, this not always 
feasible because of logistical reasons and resource constraints in 
many parts of the country. However, under certain circumstances, 
patients may well be required to be referred to another centre for 
an urgent CT or Mri scan of the brain (see 5.3.2 for indications 
for urgent CT scan).
•    Diagnostic brain imaging must be performed immediately 
on arrival at the hospital for stroke patients who are potential 
candidates for thrombolysis, to facilitate prompt treatment.
•    The brain imaging study (CT or Mri) should be interpreted by 
a physician with expertise in reading CT or Mri studies of the 
brain. Some centres prefer to use Mri scan as first-line routine 
investigation for acute stroke.
•    Diffusion-weighted Mri (DWi) is more sensitive than CT for 
detection of early ischaemic changes, and is particularly useful in 
the diagnosis of posterior circulation stroke and lacunar or small 
cortical infarctions. A DWi Mri can be negative in patients with 
definite stroke.5
•    Mri can also detect small and old haemorrhages for a prolonged 
period with T2 gradient echo sequences.6
•    Mri is particularly useful in acute stroke patients with unusual 
presentations and uncommon aetiologies, or in whom a stroke 
mimic is suspected but not clarified on CT.
•    Mri is less suited for agitated patients or for those who may vomit 
and aspirate.
•    vascular imaging may identify the site and cause of arterial 
obstruction, and identifies patients at high risk of stroke 
recurrence.
•    vascular imaging may be necessary to identify patients with tight 
symptomatic arterial stenosis who could benefit from carotid 
endarterectomy or, in highly selected individuals, cerebral artery 
angioplasty. 
•    non-invasive imaging with colour-coded duplex imaging of 
the extracranial arteries, CT angiography (CTA) or contrast-
enhanced Mr angiography (Ce-MrA) should be available at level 
3 hospitals.
•    Carotid Doppler studies are an important tool in evaluating 
patients with ischaemic stroke, and should be available at level 2 
and level 3 hospitals.
•    non-invasive approaches to visualising the vasculature are 
associated with less risk than intra-arterial angiography, which 
has a 1 - 3% risk of causing stroke in patients with symptomatic 
carotid lesions.7
•    Digital subtraction angiography (DSA) may be needed in some 
circumstances, e.g. when other tests have been inconclusive.
•    Transcranial Doppler ultrasound (TCD) is not routine and is 
currently available at only a few centres in South Africa.
•    TCD may be useful for the diagnosis of abnormalities in the large 
cerebral arteries at the base of the skull, and can be used to identify 
right-to-left cardiac shunts.8
8.4 Treatment
8.4.1 General supportive treatment to maintain 
homeostasis and treatment of complications
The term ‘general treatment’ refers to treatment strategies aimed at 
stabilising the critically ill patient to control systemic problems that 
may impair stroke recovery. The management of such problems is a 
central part of stroke treatment.9
General treatment includes respiratory and cardiac care; fluid and 
metabolic management; Bp control; the prevention and treatment of 
conditions such as seizures, venous thrombo-embolism, dysphagia, 
aspiration pneumonia, other infections and pressure ulceration, and 
occasionally management of elevated intracranial pressure.
Best level of care is in a stroke unit where patients are admitted to 
acute care under a specialist team.
Monitoring
•    There is little direct evidence from rCTs to indicate how intensively 
monitoring should be carried out, but in stroke unit trials it was 
common practice to have a minimum of 4-hourly observations for 
the first 72 hours after stroke.10
•    vital physiological functions such as blood pressure, pulse, oxygen 
saturation, blood glucose, temperature and level of consciousness 
are monitored. neurological status can be monitored using 
validated neurological scales such as the niH Stroke Scale.
•    Clinical trials using continuous telemetry suggest there may be 
some benefit from more intensive continuous monitoring in terms 
of improved detection of complications and reduced length of stay, 
but clinical outcomes are inconclusive.11,12
•    in practice, more intensive monitoring is often provided for 
subgroups of patients, such as those with reduced consciousness, 
progressing neurological deficits or a history of cardiorespiratory 
disease.
•    Close monitoring is also required for the first 24 hours after 
thrombolysis.
•    More invasive monitoring procedures, such as central venous 
catheters or intracranial pressure monitoring, are used only in 
highly selected patient groups.
Airway protection and pulmonary function
•    Adequate tissue oxygenation is important in the setting of 
acute cerebral ischaemia; supply supplemental oxygen if hypoxic. 
Common causes of hypoxia are partial airway obstruction, 
hypoventilation, aspiration pneumonia and atelectasis.
•    patients with decreased level of consciousness or signs of brainstem 
dysfunction are at greatest risk of airway compromise because of 
impaired oropharyngeal mobility and loss of protective reflexes.
•    There is a risk of airway obstruction in patients with vomiting 
or oropharyngeal muscular weakness (as in severe, bilateral or 
posterior circulation stroke).
Fluid balance
•    Many stroke patients are dehydrated on admission to hospital; this 
is associated with poor outcome.13
•    Although clinical trial evidence is limited, delivery of intravenous 
fluids is commonly considered to be part of general management 
of acute stroke, particularly in patients at risk of dehydration 
owing to reduced consciousness or impaired swallowing.
•    patients should remain nil per mouth, and fluids provided through 
intravenous line until their swallowing is formally assessed
•    Maintain normal hydration and monitor daily urine output 
accordingly.
•    normal saline (0.9%) is recommended for fluid replacement 
during the first 24 hours after stroke.
Blood pressure
•    Blood pressure is elevated in many patients with acute stroke and 
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often drops spontaneously during the first days after stroke, even 
without specific medical treatment.
•    Blood flow in the critical ischaemic penumbra of the brain (brain 
tissue that is potentially salvageable following stroke) is passively 
dependent on the mean arterial pressure, and lowering the mean 
arterial pressure may damage this area.
•    There are no adequately sized rCTs guiding Bp management. in 
the absence of reliable evidence from clinical trials, many clinicians 
have developed protocols for the management of extremely high 
Bp.
•    it is common practice in many centres to begin cautious blood 
pressure reduction when levels exceed 220 mmHg systolic and 120 
mmHg diastolic.
•    patients with markedly elevated Bp above these levels may have 
their Bp lowered; a reasonable goal would be to lower the Bp by 
15% in the first 24 hours after stroke.
•    Avoid drastic rapid reduction in Bp.
•    upper level of systolic Bp in patients undergoing thrombolytic 
therapy is 180 mmHg.
•    Avoid and treat hypotension.
Glucose metabolism
•    Hyperglycaemia after acute stroke is associated with larger infarct 
volumes and poor functional outcome.14-16
•    There is limited evidence as to whether active reduction of glucose 
in acute ischaemic stroke improves patient outcomes.
•    At present, the routine use of insulin infusion regimes in patients 
with moderate hyperglycaemia cannot be recommended.
•    it is common practice in stroke units to reduce blood glucose levels 
>180 mg/dl (10 mmol/l).10
•    use of intravenous saline and avoidance of glucose solutions in 
the first 24 hours after stroke is common practice, and appears to 
reduce blood glucose levels.17
•    Hypoglycaemia (<2.8 mmol/l) may mimic an acute ischaemic 
infarction, and should be treated by intravenous dextrose bolus or 
infusion of 10 - 20% glucose.18
•    Marked elevations in blood glucose levels should be avoided.
•    Treat hyperglycaemia with insulin when blood glucose >10 
mmol/l.
Body temperature
•    Fever is associated with poorer neurological outcome after 
stroke.19-21
•    Fever increases infarct size in experimental stroke.
•    A raised body temperature should prompt a search for infection 
and treatment where appropriate.
•    There are no adequately sized trials guiding temperature 
management after stroke.
•    it is common practice to treat fever (and its cause) when 
temperature ≥37.5°C.
swallowing and nutrition
•    nil per mouth until assessment of ability to swallow (as a matter of 
routine) because of high risk of aspiration.
•    Before testing the patient for swallowing competence, observe 
for:
•    wet phonation
•    abnormal voluntary cough
•    abnormal phonation quality
•    reduced level of consciousness
•    reduced laryngeal elevation or swallow.
•    if any of the above signs of possible aspiration are present or if 
level of consciousness is impaired, patient should remain on nil per 
mouth (fluids ivi or nasogastric tube) until swallowing formally 
assessed (often done by speech therapist).
•    All patients have their swallowing assessed before receiving aspirin. 
Aspirin could be delayed for 24 hours, so it is not necessary to put 
a nasogastric tube into every patient.
•    videofluoroscopic study may be required on selected patients, 
depending on above.
•    Swallowing difficulties usually improve within a few weeks 
after stroke but can persist, requiring long-term intervention or 
alternative feeding strategies.
•    nasogastric tube may be required for feeding and administration 
of medication.
•    nutritional intake (nasogastric feeding or oral) to be assessed and 
reviewed daily.
Recommendations
•    Organisation of in-hospital pathways and systems for acute stroke 
patients is recommended (Class III, level C).
•    Ancillary tests, as outlined in 8.3.1, are recommended (Class IV, 
GCP).
•    All stroke patients should be treated in a stroke unit (Class I, 
level A).
•    Health care systems should ensure that acute stroke patients have 
access to high-technology medical and surgical stroke care when 
required (Class III, level B).
•    in patients with suspected stroke or TiA, urgent cranial CT (Class 
I) or Mri is recommended (Class II, level A).
•    if Mri is used, the inclusion of diffusion-weighted imaging (DWi) 
and T2-weighted gradient echo sequences is recommended (Class 
II, level A).
•    in patients with TiA, minor stroke or early spontaneous recovery, 
immediate diagnostic work-up, including urgent vascular imaging 
(carotid ultrasound, CT angiography, or Mr angiography) is 
recommended (Class I, level A).
•    in patients with acute stroke and TiA, early clinical evaluation, 
including physiological parameters and routine blood tests, is 
recommended (Class I, level A).
•    Additional diagnostic examinations are necessary in selected 
patients, depending on the type of stroke and suspected aetiology 
(level IV, GCP).
•    All acute stroke (and TiA) patients should have a 12-lead eCG. 
(Class I, level A).
•    Stroke and TiA patients seen after the acute phase should have 
24-hour Holter eCG monitoring when arrhythmias are suspected 
and no other causes of stroke are found (Class I, level A).
•    intermittent monitoring of neurological status, pulse, blood 
pressure, temperature and oxygen saturation is recommended 
for 72 hours in patients with significant persisting neurological 
deficits (Class IV, GCP).
•    Oxygen should be administered if spO2 falls below 95% (Class 
IV, GCP).
•    Acute stroke patients should be on nil per mouth until assessment 
of ability to swallow (Class IV, GCP).
•    regular monitoring of fluid balance and electrolytes is recommended 
in patients with severe stroke or swallowing problems (Class IV, 
GCP).
•    normal saline (0.9%) is recommended for fluid replacement 
during the first 24 hours after stroke (Class IV, GCP).
•    routine blood pressure lowering is not recommended following 
acute stroke (Class IV, GCP).
•    Cautious blood pressure lowering is recommended in patients with 
any of the following: extremely high Bp (>220/120 mmHg) on 
repeated measurements, or severe cardiac failure, aortic dissection 
or hypertensive encephalopathy (Class IV, GCP).
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•    Abrupt Bp lowering should be avoided (Class II, level C).
•    low Bp secondary to hypovolaemia or associated with neurological 
deterioration in acute stroke should be treated with volume 
expanders (Class IV, GCP).
•    Monitoring serum glucose levels is recommended (Class IV, 
GCP).
•    Treatment of serum glucose levels >10 mmol/l with insulin 
titration is recommended (Class IV, GCP).
•    Severe hypoglycaemia <2.8 mmol/l should be treated with 
intravenous dextrose or infusion of 10 - 20% glucose (Class IV, 
GCP).
•    The presence of pyrexia (temperature >37.5°C) should prompt a 
search for concurrent infection (Class IV, GCP).
•    Treatment of pyrexia (>37.5°C) with paracetamol, fanning and 
tepid sponging is recommended (Class III, level C).
•    Antibiotic prophylaxis is not recommended in immunocompetent 
patients (Class II, level B).
8.4.2  specific treatment
8.4.2.1  Intravenous thrombolysis for acute ischaemic stroke
•    intravenous thrombolytic therapy with recombinant tissue 
plasminogen activator (tpA) is an accepted therapy for acute 
ischaemic stroke within 4.5 hours of onset.
•    intravenous tpA should be administered at a hospital with rapid 
triage of stroke patients and established protocols for use of tpA 
(where there is a strict adherence to inclusion and exclusion 
criteria) and where good post-treatment care is available.
•    intravenous tpA (0.9 mg/kg body weight, maximum 90 mg, with 
10% of the dose given as a bolus and the remainder given by a 
60-minute infusion) given within 3 hours after ischaemic stroke 
onset, significantly improves outcome.22-24
•    The eCASS iii trial has shown that intravenous tpA administered 
between 3 and 4.5 hours after symptom onset significantly 
improves clinical outcomes in patients with acute ischaemic 
stroke, compared with placebo.25
•    Treatment benefit is time-dependent and the number needed to 
treat (nnT) to get one more favourable outcome drops from 4 
during the first 90 minutes through to 7 at 3 hours, and towards 
14 between 3 and 4.5 hours.24,25
•    Thrombolytic therapy should only be given if the diagnosis is 
established by a physician with expertise in the diagnosis of stroke 
and who is aware of the risks of this treatment.
•    imaging of the brain (CT scan or Mri) must be done prior to 
treatment with tpA and assessed by physicians with expertise in 
reading and interpreting the imaging study and when haemorrhage 
is excluded.
•    imaging of the brain must be available 24 hours per day and 
available as an emergency on request.
•    Bp must be below 185/110 mmHg before and for the first 24 hours 
after thrombolysis. Management of high Bp is required as protocol 
deviations are associated with higher mortality rates.22,26,27
•    A laboratory service should also be available 24 hours/day at the 
hospital.
•    inclusion criteria for treatment of acute ischaemic stroke with 
intravenous tpA:
•    diagnosis of ischaemic stroke causing measurable neurological 
deficit
•    neurological signs should not be clearing spontaneously
•    neurological signs should not be minor and isolated
•    stroke symptoms should not be suggestive of subarachnoid 
haemorrhage
•    onset of symptoms should be <4.5 hours before beginning 
treatment, and caution should be exercised in treating a patient 
with major deficits (niHSS score ≥20).
National Institute of Neurological Disorders and stroke (NINDs) 
exclusion criteria for intravenous tPA
•    time of onset of symptoms unknown or >3 hours (data from 
eCASS iii trial support 4.5 hour cut-off)
•    minor or rapidly improving stroke symptoms
•    CT or Mri signs of haemorrhage
•    history of previous intracranial haemorrhage
•    head trauma or prior stroke in previous 3 months
•    myocardial infarction in the previous 3 months
•    gastro-intestinal or urinary tract haemorrhage in previous 21 
days
•    major surgery in previous 14 days
•    arterial puncture at a non-compressible site in the previous 7 days
•    history of previous intracranial haemorrhage
•    systolic Bp >185 mmHg, diastolic >110 mmHg. if Bp can be 
lowered safely with antihypertensive agents, the patient may be 
eligible for treatment. Doctors must assess Bp stability before 
starting rt-pA. As time is limited, some patients with markedly 
elevated Bp cannot be managed adequately and still meet the 
3-hour requirement.
•    evidence of active bleeding or acute trauma on examination
•    patient taking an oral anticoagulant or, if anticoagulant being 
taken, inr >1.5
•    if patient received heparin in the previous 48 hours, a pTT must 
not be above the normal range
•    platelet count <100 000 ×109/l
•    blood glucose <2.7 mmol/l
•    seizure at stroke onset with post-ictal residual neurological 
impairment with uncertainty if deficit owing to ischaemic stroke
•    CT scan shows multilobar infarction (hypodensity greater than a 
third of the cerebral hemisphere)
•    patient or family members do not understand the potential risks 
and benefits of treatment.
Other thrombolytic agents
Clinical trials of streptokinase were halted prematurely because of 
unacceptably high rates of haemorrhage; this agent should not be 
used. Other intravenously administered thrombolytic agents have not 
been tested extensively for treatment of patients with acute ischaemic 
stroke and should be avoided in routine clinical practice outside the 
context of a clinical trial.
Dosage of intravenous tPA
The dose is 0.9 mg/kg (maximum 90 mg), with 10% given as an 
intravenous bolus and the rest infused intravenously over 1 hour. The 
use of intravenous streptokinase or other thrombolytic agents apart 
from tpA is not recommended.
8.4.2.2 Endovascular therapy
•    There are no rCTs comparing intra-arterial tpA with intravenous 
tpA, which is the presently accepted standard of care.
•    The limited trials (intra-arterial route) available are often 
characterised by inadequate controls, no good outcome studies, 
and small sample sizes.28
•    The results of these studies are therefore not at present robust 
enough to warrant recommendation for use in routine care outside 
specialist units.
•    The availability of intra-arterial thrombolysis should generally 
not preclude the intravenous administration of tpA in otherwise 
eligible patients. intra-arterial thrombolysis with or without 
mechanical clot disruption is an option for treatment of selected 
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patients who have a major ischaemic stroke of ≤6 hours duration 
owing to occlusion of the middle cerebral or basilar artery who 
are not otherwise candidates for intravenous tpA.29-32 This type 
of treatment requires that the patient be at a specialist stroke 
centre with experienced stroke clinicians with immediate access to 
cerebral angiography and qualified interventionists.
•    patients who are evaluated within 6 hours of symptoms but who 
are ineligible to receive intravenous thrombolysis because of recent 
surgery or other procedures, may be candidates for intra-arterial 
thrombolysis.33,34
•    Studies comparing standard intravenous tpA with a combined 
intravenous and intra-arterial approach have started.35
•    it is uncertain as to whether or not the use of extraction devices 
(such as the Merci device) are better than intra-arterial delivery of 
TpA with catheter tip mechanical clot disruption.
•    recanalisation has been used as a surrogate for outcome, 
but outcome depends on when recanalisation occurs – late 
recanalisation may not be associated with good outcome but could 
lead to increased complications; more data are needed.
•    Only a minority of stroke patients in South Africa are likely to 
qualify for intra-arterial thrombolysis at present (given the time 
limits, resource constraints, lack of comprehensive stroke units 
and availability of expertise) – and then at least 2 requirements will 
need to be met: arterial occlusion is proven and that the occlusion 
is reachable with interventional techniques.
8.4.2.3 Early antiplatelet treatment after acute ischaemic stroke
•    Aspirin started within 48 hours of ischaemic stroke is safe and 
effective, resulting in a modest net benefit with significantly fewer 
recurrent strokes. Aspirin was tested in large rCTs in acute (<48 
hours) stroke, and a significant reduction was seen in death and 
dependency and recurrence of stroke (9 fewer deaths or non-fatal 
strokes per 1 000 in the first few weeks, and 13 fewer dead or 
dependent per 1 000 after some weeks’ or months’ follow-up).36,37
•    The use of other antiplatelet agents such as clopidogrel or 
dipyridamole in the setting of acute ischaemic stroke has not been 
evaluated.
•    A phase 3 trial for the glycoprotein-iib-iiia antagonist abciximab was 
stopped prematurely because of an increased rate of bleeding.39
8.4.2.4 Anticoagulation for acute ischaemic stroke 
•    results of recent trials show that early administration of 
either heparin or low-molecular-weight heparin fail to show 
net benefit and are associated with an increased risk of bleeding 
complications.36,39-41
•    early anticoagulation increased the risk of symptomatic 
haemorrhages, especially among persons with larger infarcts.42
•    These medications are also associated with a risk of serious 
bleeding in other parts of the body, although the likelihood 
of bleeding appears to be lower than that associated with the 
administration of thrombolytic agents.
•    present data indicate that early administration of heparin or low-
molecular-weight heparin does not lower the risk of early recurrent 
stroke, including among patients with cardio-embolic stroke.
•    early administration of anticoagulants does not lessen the risk of 
early neurological worsening.
•    Data are not sufficient to indicate whether anticoagulants might 
have efficacy among potentially high-risk groups such as persons 
with intracardiac or intra-arterial thrombi.
•    The efficacy of urgent anticoagulation is not established for 
treatment of patients with vertebrobasilar disease or an arterial 
dissection.
•    Most trials have not demonstrated the efficacy of anticoagulation 
in improving outcomes of acute ischaemic stroke.
•    The role of anticoagulants as an adjunctive therapy in addition 
to pharmacological or mechanical thrombolysis has not been 
defined.
•    low-dose subcutaneous heparin or low-molecular-weight heparin 
should be considered for patients at high risk of deep-vein 
thrombosis or pulmonary embolism.
8.4.2.5  Neuroprotection for acute ischaemic stroke
Currently no clinical trials have shown benefit for treatment of acute 
ischaemic stroke with neuroprotective agents.
Intracerebral haemorrhage
This guideline does not include the management of intracerebral 
haemorrhage; this has been fully discussed in the American 
guideline.43
Recommendations
•    intravenous tpA (0.9 mg/kg, maximum 90 mg) with 10% of 
dose given as a bolus followed by infusion lasting 60 minutes 
is recommended within 4.5 hours of onset of ischaemic stroke 
(Class I, level A), provided there are no contraindications for 
the treatment, although treatment between 3 and 4.5 hours is 
currently not included in the South African labelling.
•    in specialised (level 3) stroke centres, intra-arterial treatment of 
acute middle cerebral artery occlusion within ≤6 hours of the 
event is an option (Class II, level B).
•    The availability of intra-arterial thrombolysis should generally 
not preclude the intravenous administration of tpA in otherwise 
eligible patients (Class I, level A).
•    intra-arterial thrombolysis is recommended for acute basilar 
occlusion in selected patients (Class III, level B), and intravenous 
thrombolysis for basilar occlusion is an acceptable alternative even 
after 3 hours (Class III, level B).
•    Aspirin (150 - 300 mg loading dose) should be given within 48 
hours after ischaemic stroke (Class I, level A).
•    if thrombolytic therapy is planned or given, aspirin or other 
antithrombotic therapy should not be initiated within 24 hours 
(Class IV, GCP).
•    The use of other antiplatelet agents (single or combined) is not 
recommended in the setting of acute ischaemic stroke (Class III, 
level C).
•    The administration of glycoprotein-iib-iiia inhibitors is not 
recommended (Class I, level A).
•    The early administration of unfractionated heparin, low-molecular-
weight heparin or heparinoids is not recommended for the 
treatment of patients with acute ischaemic stroke (Class I, level 
A).
•    There is no recommendation to treat ischaemic stroke patients 
with neuroprotective substances (Class I, level A).
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9. Management of neurological 
complications of acute ischaemic 
stroke
9.1 Acute brain oedema and raised 
intracranial pressure
•    patients with large infarctions affecting the cerebral hemisphere 
or cerebellum are at high risk for complicating brain oedema and 
increased intracranial pressure.
•    Close monitoring of a patient for signs of neurological worsening 
during the first few days after stroke is recommended.
•    Basic management of stroke patients with raised intracranial 
pressure includes head positioning at an elevation of up to 30°, 
avoidance of noxious stimuli, pain relief, appropriate oxygenation 
and normalising body temperature.
•    Malignant middle cerebral artery (MCA) syndrome. patients 
with massive space-occupying hemispheric infarction have a 
poor prognosis. life-threatening brain oedema usually develops 
between the 2nd and 5th day after stroke onset, but up to a third 
of patients can have neurological deterioration within 24 hours 
after symptom onset.1,2 Decompressive surgery for malignant 
oedema of the cerebral hemisphere (malignant middle cerebral 
artery syndrome) may be life saving.3,4 A pooled analysis of 93 
patients from 3 trials that evaluated decompressive surgery for the 
treatment of malignant infarction of the middle cerebral artery 
showed that, compared with the control group that received 
conservative medical therapy, at 1 year the probability of survival 
increased from 28% in the control group to nearly 80% in patients 
in the decompressive surgery group, and the probability of 
survival with a mild or moderate disability (mrS ≤3) doubled 
(21% v. 43%). However, the probability of surviving in a condition 
requiring assistance from others (mrS of 4) increases (2% v. 
31%), although the risk of very severe disability (mrS of 5) is 
not increased (5% v. 4%) by decompressive surgery.3 inclusion 
criteria for this combined analysis were age 18 - 60 years, niHSSS 
>15, decrease in level of consciousness to a score ≥1 on item 1a 
of the niHSS, infarct signs on CT of 50% or more of the MCA 
territory or >145 cm³ on DWi, and inclusion <45 hours after 
onset (surgery <48 hours). A systematic review of 12 observational 
retrospective studies found age >50 years to be a predictor of poor 
outcome.5 even patients with aphasia may improve significantly.6 
The decision to perform decompressive surgery in an individual 
patient with space-occupying hemispheric infarction will depend 
on the willingness to accept survival with moderate disability, the 
age of the patient, and subsequent access to rehabilitation. Many 
hospitals do not have neurosurgical expertise, and transfer of 
patients at risk for malignant brain oedema to an institution with 
such expertise should be considered, particularly for the younger 
patient.
•    Medical management. There is no rCT evidence to support the 
use of medical therapy in patients with large space-occupying 
infarctions and brain oedema. However, some stroke clinicians 
consider the use of the following agents despite the lack of 
evidence: intravenous glycerol (4×250 ml of 10% glycerol over 
30 - 60 minutes) or mannitol (25 - 50 g every 3 - 6 hours).7,8 
Hypotonic and glucose-containing solutions should be avoided 
as replacement fluids. Dexamethasone and corticosteroids are not 
useful.9
•    large cerebellar infarctions. large cerebellar infarctions may 
require urgent decompression (shunting or surgical evacuation). 
The operation should be performed before signs of herniation are 
present. The prognosis among survivors can be very good, even in 
patients who are comatose before surgery.
9.2 seizures
•    Seizures may occur in the acute phase of ischaemic stroke. Anti-
epileptic drugs should be used, based on general principles of 
seizure management.
•    There is no evidence that primary prophylactic anticonvulsive 
treatment is beneficial.
9.3 Agitation
Agitation and confusion may be a consequence of acute stroke, but 
may also be due to complications such as fever, volume depletion or 
infection. Adequate treatment of the underlying cause must precede 
any type of sedation or antipsychotic treatment.
Recommendations
•    Medical treatment including osmotherapy, for treatment of 
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deteriorating patients with malignant brain oedema after large 
cerebral infarction is unproven (Class III, level C).
•    Hyperventilation is a short-lived intervention.
•    Corticosteroids are not recommended for treatment of cerebral 
oedema because of lack of evidence of efficacy (Class III, level 
A).
•    it is recommended that ventriculostomy or surgical decompression 
be considered for treatment of large cerebellar infarctions that 
compress the brainstem (Class III, level C).
•    Decompressive surgery should be considered within 48 hours 
of symptom onset for patients with evolving malignant oedema 
of the cerebral hemisphere, but physicians should advise the 
patient’s family about the potential outcomes including survival 
and disability (Class I, level A). Both the age of the patient and 
the side of infarction may affect decisions about surgery. Age >50 
years is a predictor of poor outcome.
•    prophylactic administration of anticonvulsants is not 
recommended.
•    recurrent seizures after stroke should be treated as in other 
neurological conditions.
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10. Management of common systemic 
complications of acute ischaemic 
stroke
10.1 Prevention of DVT and PE
•    early hydration and mobilisation can potentially reduce the risk 
of DvT and pe.
•    Graded compression stockings have not been shown to be effective 
in preventing venous thrombo-embolism after stroke. Data from 
the ClOTS trial do not lend support to the use of thigh-length 
stockings in patients admitted to hospital with acute stroke.1
•    low-dose low-molecular-weight heparins reduced the incidence 
of both DvT and pe in stroke patients, without an increased risk 
of intracerebral or extracerebral haemorrhage (nnT: 7 and 38 for 
DvT and pe, respectively).
•    low-dose unfractionated heparin decreased the thrombosis risk but 
had no influence on pulmonary embolism. The risk of intracranial 
haemorrhage was not statistically significantly increased.2
•    prophylaxis with low-molecular-weight heparins or subcutaneous 
low-dose unfractionated heparin (5 000 iu twice daily) is indicated 
in patients at high risk of DvT or pe (e.g. due to immobilisation, 
obesity, diabetes, previous stroke).3,4
10.2 Aspiration and pneumonia
•    Bacterial pneumonia is an important complication in stroke 
patients, and is mainly caused by aspiration.5,6
•    Aspiration is frequently found in patients with reduced 
consciousness and in those with swallowing disturbances.
•    Oral feeding should be withheld until the patient has demonstrated 
intact swallowing with small amounts of water and intact 
coughing on command. nasogastric (nG) or percutaneous enteral 
gastrostomy (peG) feeding may prevent aspiration pneumonia, 
although reflux of liquid feed, hypostasis, diminished cough and 
immobilisation increase the risk.
•    Frequent changes of the patient’s position in bed and pulmonary 
physical therapy may prevent aspiration pneumonia.
10.3 Dysphagia and feeding
•    Dysphagia occurs in up to 50% of patients with unilateral 
hemiplegic stroke.7 
•    The prevalence of dysphagia is highest in the acute stages of stroke, 
and declines to around 15% at 3 months.8
•    Dysphagia is associated with a higher incidence of medical 
complications and increased overall mortality.7
•    Withholding or limiting oral intake can worsen the catabolic state 
that may be associated with an acute illness such as stroke.
•    estimates of the incidence of malnutrition vary from 7 - 15% at 
admission to 22 - 35% at 2 weeks.9-11
•    Malnutrition predicts a poor functional outcome and increased 
mortality.12-14
•    routine supplementation for all acute stroke patients has not been 
shown to improve outcomes or reduce complications.15 There 
are no adequately powered trials of targeting supplementation to 
stroke patients at high risk of malnutrition.
•    For patients with continuing dysphagia, options for enteral 
nutrition include nG or peG feeding.
•    A trial of early (median 48 hours post-stroke) versus delayed (1 
week) nG feeding found no significant benefit of early feeding, 
although there was a trend to fewer deaths in the early nG 
group.15
•    in a trial examining peG and nG feeding within 30 days, peG 
feeding was no better than nG and in fact was potentially 
harmful.15
•    peG feeding has also been studied in longer-term dysphagia, and 
two trials comparing peG and nG feeding found a trend towards 
improved nutrition with peG feeding that did not reach statistical 
significance.16,17
•    Studies that have addressed quality of life found it was not 
improved by peG feeding.18,19
10.4 Pressure ulcers
•    in patients at high risk of developing pressure ulcers, use of support 
surfaces, frequent repositioning, optimising nutritional status, and 
moisturising sacral skin are appropriate preventive strategies.20 
An air-filled or fluid-filled mattress may be useful for patients at 
high risk.
•    The skin of the incontinent patient must be kept dry.
10.5 Urinary tract infections and incontinence
The majority of hospital-acquired urinary tract infections are 
associated with the use of indwelling catheters.21,22 intermittent 
catheterisation has not been shown to reduce the risk of infection. 
Once urinary infection is diagnosed, appropriate antibiotics should 
be chosen. prophylactic antibiotics are best avoided to prevent 
bacterial resistance developing.
•    urinary incontinence is common after stroke, particularly in older, 
more disabled and cognitively impaired patients, and is a strong 
predictor of poor functional outcome, even after correcting for age 
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and functional status.23,24 However, data from the available trials 
are insufficient to guide continence care of adults after stroke.22,25
•    professional input through structured assessment and management 
of care and specialist continence nursing may reduce urinary 
incontinence and related symptoms after stroke and improve 
continence rates in both inpatients and outpatients.22,26
•    Trials of interventions are insufficient in number and quality to 
make any firm recommendations.25
10.6 Falls
•    Falls are common (up to 25%) after stroke in the acute setting, 
during inpatient rehabilitation, and in the long term.27-29
•    risk factors for falls in stroke survivors include cognitive impairment, 
depression, polypharmacy and sensory impairment.30-32
•    A multidisciplinary prevention approach that focuses on personal 
and environmental factors has been found to be successful in 
general rehabilitation settings.33,34
Recommendations
•    infections after stroke should be treated with appropriate 
antibiotics (Class IV, GCP).
•    prophylactic administration of antibiotics is not recommended 
(Class II, level B).
•    early rehydration is recommended to reduce the incidence of 
venous thromboembolism (Class IV, GCP).
•    Graded stockings are not recommended.
•    early mobilisation is recommended to prevent complications 
such as aspiration pneumonia, DvT and pressure ulcers (Class 
IV, GCP).
•    low-molecular-weight heparins or low-dose subcutaneous heparin 
should be considered for patients at high risk of DvT or pe (Class 
I, level A).
•    in stroke patients with urinary incontinence, specialist assessment 
and management is recommended (Class III, level C).
•    Swallowing assessment is recommended, but there are insufficient 
data to recommend a specific approach for treatment (Class III, 
GCP).
•    early commencement of nasogastric (nG) feeding (within 
48 hours) is recommended in stroke patients with impaired 
swallowing (Class II, level B).
•    percutaneous enteral gastrostomy (peG) feeding should not be 
considered in stroke patients in the first 2 weeks (Class II, level 
B).
•    Oral dietary supplements are only recommended for non-dysphagic 
stroke patients who are malnourished (Class II, level B).
•    An assessment of falls risk is recommended for every stroke patient 
(Class IV, GCP).
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11. Management of transient 
ischaemic attack (TIA), stroke with 
spontaneous recovery, and minor non-
disabling stroke
11.1 Definition and causes of TIA
•    Transient ischaemic attack (TiA) is defined as a neurological deficit 
lasting <24 hours that is attributed to focal cerebral or retinal 
ischaemia.1
•    The diagnosis is generally based on clinical history alone and 
specifically on the recollections and medical records of the patient 
who was neurologically impaired during the event.
•    The initial aim of the requirement that resolution of symptoms 
occur within 24 hours was to exclude patients with infarction.
•    However, infarctions can occur in those without persistent 
neurological deficits; evidence of acute infarction is identified by 
Mri in up to 50% of patients who meet the criteria for TiA.2
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•    About 15 to 20% of patients with stroke have a preceding TiA.3
•    The causes of TiA (such as atrial fibrillation (persistent or 
paroxysmal), carotid artery or vertebrobasilar artery disease 
(vessel to vessel embolisation or haemodynamic ischaemia) and 
large- and small-artery disease in the brain) are the same as those 
for stroke, so strategies to prevent further attacks are similar to 
those for stroke.
11.2 Risk of stroke after TIA or minor non-
disabling stroke
•    in a large north American study of patients presenting to the 
emergency units of 16 hospitals with physician-diagnosed TiA, 
10.5% returned within 90 days of the index TiA with a stroke, but 
half of this risk is incurred within the first 2 days of the TiA. Of 
these strokes, 21% were fatal and 64% were disabling.4
•    Other studies have confirmed a high risk of early stroke after 
TiA.5
•    patients with minor non-disabling stroke and rapid spontaneous 
clinical recovery are also at high risk of recurrent stroke or TiA.6,7
•    The early risk of stroke is higher after posterior circulation territory 
events.8
•    The risk of stroke after non-retinal TiA attributable to a 70 - 99% 
stenosis of the internal carotid artery exceeded 25% within 3 
months of the TiA.9
11.3 Evaluation of patients after TIA
•    TiA is often a neglected condition, and patients with TiA are 
frequently incorrectly managed without urgency and investigated 
1 - 2 weeks later.
•    TiA symptoms are often ignored by the patient or unrecognised 
by the doctor.
•    A detailed history is most helpful in determining potential causes 
of an episode of neurological impairment that appears consistent 
with a TiA.
•    A full cardiovascular examination is an essential component of 
the evaluation of a patient with TiA. An eCG is recommended on 
all such patients, and further cardiac tests (e.g. echocardiography, 
Holter) may be required, depending on history and cardiovascular 
clinical examination.
•    The neurological examination may identify persistent deficits that 
clarify the cause of the event.
•    Simple clinical scoring systems can be used to identify patients at 
particularly high risk.5
•    ABCD2 score allows identification of groups at especially high 
risk in whom aggressive evaluation and urgent intervention is 
justified.10
•    laboratory tests (blood glucose, electrolytes, eSr, full blood count) 
may be useful in identifying TiA mimics (e.g. hypoglycaemia, 
hyponatraemia) or potential causes of the TiA (e.g. thrombocytosis, 
endocarditis, temporal arteritis).
•    Carotid artery imaging is important to identify internal carotid 
artery stenosis as a cause of the TiA. Such imaging can be 
performed with Doppler ultrasonography, CT or Mri angiography. 
The latter two methods can also be used to image the vertebral 
arteries in the neck or the intracranial arteries, to identify a 
stenosis or dissection.
•    CT brain scan or Mri may reveal evidence of acute infarction even 
if the patient has no symptoms or signs of stroke. Other mimics 
of TiA such as brain tumour or subdural haematoma may also be 
revealed.
11.4 Treatment
11.4.1 Rapid assessment
•    rapid assessment and intervention is the new standard for TiA 
care.
•    immediate preventive treatment ( see 11.4.2 to 11.4.8 below) will 
reduce stroke, disability and death.11,12
•    patient with TiA or minor non-disabling stroke require urgent 
clinical diagnosis to treat associated general abnormalities, modify 
active risk factors, identify specific treatable causes (particularly 
arterial stenosis and other embolic sources), and initiate secondary 
prevention to prevent stroke.
•    Carotid artery imaging is a priority in those patients with TiA 
or minor stroke, more so than in those with major stroke where 
surgery is not going to be of benefit in the short term.
11.4.2 Aspirin and other antiplatelet agents
•    Aspirin reduces the long-term risk of stroke and cardiovascular 
events after stroke or TiA with an overall reduction in risk of 
22%.13
•    Other antiplatelet drugs have not been tested specifically after TiA 
or as a treatment immediately after ischaemic stroke. in secondary 
prevention studies in patients with stroke, clopidogrel was slightly 
more effective than aspirin in reducing the risk of vascular events, 
and the combination of extended-release dipyridamole and aspirin 
was superior to aspirin alone in reducing the risk of stroke among 
patients who had previously had a stroke or TiA.14-16
11.4.3 Anticoagulant therapy
•    Anticoagulation has not been evaluated specifically in patients with 
TiA but has been extensively evaluated after ischaemic stroke.
•    in patients with stroke and atrial fibrillation, long-term oral 
anticoagulation reduces the risk of recurrent stroke.17
•    Oral anticoagulation after non-cardiac ischaemic stroke is not 
superior to aspirin, and causes more bleeding.18-20
11.4.4 Carotid endarterectomy (CEA)
•    CeA performed soon after TiA or minor stroke (see below) 
reduces the risk of recurrent disabling stroke or death (rr 0.52) 
in patients with severe (70 - 99%) ipsilateral internal carotid artery 
stenosis (grading according to nASCeT criteria).21-24
•    CeA should only be performed in centres with a perioperative 
complication rate (all strokes and death) <6%.
•    Men with less severe ipsilateral carotid stenosis (50 - 69%) and 
very recent hemispheric symptoms may also benefit, provided 
the centre has a perioperative complication rate (all strokes and 
death) <3%.24
•    Women with severe (>70%) symptomatic stenosis should undergo 
CeA, whereas women with more moderate stenosis should be 
treated medically.25
•    Surgery is potentially harmful in patients with mild or moderate 
degrees of stenosis (<50%).24
•    Older patients (>75 years) without organ failure or serious cardiac 
dysfunction benefit from CeA.26
•    patients with amaurosis fugax, severe stenosis and a high risk 
profile should be considered for CeA; those with amaurosis fugax 
and few risk factors do better with medical treatment.
•    patients with mild-to-moderate intracranial stenosis and severe 
extracranial stenosis should be considered for CeA.
•    The benefit from CeA is less in patients with lacunar stroke.27
•    patients with leukoaraiosis carry an increased perioperative risk.28
•    Occlusion of the contralateral internal carotid artery (iCA) is not a 
contraindication to CeA but carries a higher perioperative risk.
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11.4.5 Timing of surgery for carotid stenosis after TIA 
or minor stroke
•    The benefit from surgery is greatest in patients randomised within 
2 weeks after the last ischaemic event, and falls rapidly with 
increasing delay (numbers needed to treat = 5 within 2 weeks 
and falls to 125 after 12 weeks to prevent 1 ipsilateral stroke in 5 
years).26
•    no difference in operative complications observed between early 
(<3 - 6 weeks) and late (>3 - 6 weeks) surgery in stable patients.
11.4.6 Carotid angioplasty and stenting (CAs)
Several trials have compared CAS and CeA in secondary stroke 
prevention.29-32 An updated meta-analysis of these studies revealed 
a significantly higher risk of any stroke and death within 30 days 
after CAS, compared with CeA (Or 1.41; 95% Ci 1.07 - 1.87; 
p=0.016). However, significant heterogeneity was found in this 
analysis (p=0.035).33 After the periprocedural period, few ipsilateral 
strokes occurred with either procedure. 
11.4.7 Intracranial and vertebral artery occlusive 
disease
•    extracranial-intracranial anastomosis between the superficial 
temporal and middle cerebral arteries is not beneficial in preventing 
stroke in patients with MCA or iCA stenosis or occlusion.34
•    patients with symptomatic intracranial stenoses ≥50 % are at 
high risk of recurrent strokes, both in the anterior and posterior 
circulation (12% after 1 year and 15% after 2 years in the territory 
of the stenosed artery).35,36
•    Severe stenoses (≥70%) carry a higher risk than moderate stenoses 
(>50, <70%).36
•    After stenting, recurrent strokes are reported in about 5 - 7% 
of patients with moderate or severe stenoses after 1 year, and in 
around 8% after 2 years. However, the incidence of complications 
after either angioplasty or stenting may be up to 6%.37-41
•    no rCTs have evaluated angioplasty, stenting or both for 
intracranial stenosis. Several non-randomised trials have shown 
feasibility and acceptable safety of intracranial stenting, but the 
risk of re-stenosis remains high.41,42
•    Stenting of the extracranial segments of the vertebral artery is 
technically feasible with a moderate periprocedural risk as for 
example demonstrated in the SSylviA trial; but especially at the 
origin there is a particularly high rate of re-stenosis.42
•    endovascular procedures should only be undertaken in specialised 
comprehensive stroke centres that have experienced stroke 
neurologists or physicians (who are aware of risks/benefits) working 
with a highly skilled and properly trained neuro-interventionalist.
11.4.8 Treatment of risk factors for cardiovascular 
disease
Other medical interventions that reduce the risk of stroke among 
patients with a history of stroke or coronary artery or pvD are also 
likely to reduce the risk of vascular events after TiA (see Chapter 12, 
Secondary prevention).
Recommendations
•    patients with suspected TiA, or minor stroke with early spontaneous 
recovery, should be evaluated as soon as possible after an event 
(Class I, level A). 
•    in patients with suspected TiA or stroke, urgent cranial CT (Class 
I) or Mri (Class II), is recommended within 24 hours of symptom 
onset (level A). 
•    if Mri is used, the inclusion of diffusion-weighted imaging (DWi) 
and T2-weighted gradient echo sequences is recommended (Class 
II, level A).
•    non-invasive imaging of the cervicocephalic vessels should be 
performed urgently and routinely as part of the evaluation of 
patients with suspected TiA (Class I, level A).
•    non-invasive testing of the intracranial vasculature reliably 
excludes the presence of intracranial stenosis (Class I, level A) 
and is reasonable to obtain when knowledge of intracranial steno-
occlusive disease will alter management.
•    eCG should be done as soon as possible after a TiA (Class I, level 
B). prolonged cardiac monitoring (inpatient telemetry or Holter 
monitor) is useful in patients with an unclear origin after initial 
brain imaging and echocardiography (Class II, level B).
•    echocardiography is reasonable in the evaluation of patients with 
suspected TiAs, especially in patients in whom no cause has been 
identified by other elements of the workup (Class II, level B).
•    routine blood tests (complete blood count, eSr, blood glucose 
and fasting lipids) are reasonable in the evaluation of patients with 
suspected TiAs (Class II, level B).
•    CeA is recommended for patients with 70 - 99% stenosis (Class 
I, level A). CeA should only be performed in centres with a 
perioperative complication rate (all strokes and death) <6% (Class 
i, level A).
•    CeA should be performed as soon as possible after the last 
ischaemic event, ideally within 2 weeks (Class II, level B). 
•    CeA may be indicated for certain patients with stenosis of 50 - 
69%; males with very recent hemispheric symptoms are most likely 
to benefit (Class III, level C). CeA for stenosis of 50 - 69% should 
only be performed in centres with a perioperative complication 
rate (all stroke and death) <3% (Class I, level A).
•    CeA is not recommended for patients with stenosis <50% (Class 
I, level A).
•    patients should remain on antiplatelet therapy both before and 
after surgery (Class I, level A).
•    Carotid percutaneous transluminal angioplasty and/or stenting 
(CAS) is only recommended in selected patients (Class I, level 
A). it should be restricted to the following subgroups of patients 
with severe symptomatic carotid artery stenosis: those with 
contraindications to CeA, stenosis at a surgically inaccessible site, 
re-stenosis after earlier CeA, and post-radiation stenosis (Class 
IV, GCP). patients should receive a combination of clopidogrel 
and aspirin immediately before and for at least 1 month after 
stenting (Class IV, GCP).
Risk stratification: ABCD2 score:
Age:  <60 = 0; >60 = 1
Bp:  Systolic Bp <140 and/or diastolic Bp <90 = 0
 Systolic Bp >140 and/or diastolic Bp >90 = 1
Clinical: unilateral weakness = 2
 speech disturbance without weakness = 1
 other symptoms = 0
Duration: <10 min = 0
 10 - 59 min = 1
 >59 min = 2
Diabetes: present = 1
Scores 0 - 3: low risk (risk of stroke within 2 days of TiA: 1%)
Scores 4 - 5: moderate risk (risk of stroke within 2 days of TiA: 4.1%)
Scores 6 - 7: high risk (risk of stroke within 2 days of TiA: 8.1%)
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•    endovascular revascularisation by intravascular balloon angioplasty 
and/or stenting may be considered for patients with symptomatic 
severe intracranial stenoses (70% luminal narrowing) despite 
optimal medical therapy (Class IV, GPC). Such procedures should 
be undertaken in specialised stroke centres.
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persons consuming no alcohol at all. There are no specific data on 
secondary prevention.
12.6 Weight reduction
A BMi >25 and abdominal obesity (defined by waist circumference 
>102 cm in men and >88 cm in women) are associated with an 
increased risk for ischaemic stroke.11,12 
12.7 Physical activity
physical activity reduces the risk for stroke but there are no specific 
data on secondary prevention.13
12.8 Platelet-inhibiting (antithrombotic) 
medication
•    Aspirin reduces the risk for a subsequent cerebrovascular event 
after ischaemic stroke or TiA.14,15
•    Clopidogrel is marginally more effective than aspirin in secondary 
stroke prevention.16
•    The benefit of clopidogrel over aspirin is amplified in diabetics 
and patients with recurrent ischaemic strokes and myocardial 
infarctions.17,18
•    The combination of extended release dipyridamole plus aspirin 
offers a small additional benefit over aspirin alone in reducing the 
chance of subsequent stroke.19,20
12.9 Anticoagulation
•    Oral anticoagulation with warfarin is superior to aspirin in 
secondary stroke prevention for patients with non-valvular 
or valvular atrial fibrillation (AF), provided that intracranial 
haemorrhage has been excluded and the treatment can be properly 
supervised. The optimal inr for secondary stroke prevention in 
patients with AF is between 2.0 and 3.0.21-23
•    Selected patients with proven cardio-embolic stroke benefit from 
anticoagulation with warfarin.24
•    Anticoagulation with warfarin (inr 2.5 - 3.5) is superior to 
aspirin-based platelet-inhibiting drug regimens in the prevention 
of stroke in patients with mechanical prosthetic heart valves.25
•    Oral anticoagulation is not recommended in patients with 
co-morbid conditions such as falls, poor compliance, uncontrolled 
epilepsy and gastro-intestinal bleeding.
•    increasing age alone is not a contra-indication to oral 
anticoagulation.
12.10 Vascular interventions 
See paragraphs 11.4.4 to 11.4.6.
12.11 Patent foramen ovale (PFO)
•    Case reports and case control studies indicate an association 
between the presence of pFO and cryptogenic stroke in both 
younger and older stroke patients.26,27
•    Two population-based studies pointed in the same direction but 
did not confirm a significant association.28,29
•    in patients with pFO alone, the overall risk of recurrence is low. 
However, when pFO is combined with an atrial septal aneurysm, 
a eustachian valve or a Chiari network, or in patients who have 
suffered more than one stroke, the risk of recurrence can be 
substantial.30
•    endovascular closure of pFOs with or without septal aneurysms 
is feasible in such patients and may lower the risk of recurrent 
stroke compared with medical treatment; however, rCTs are still 
lacking.31,32
12.12 sleep-disordered breathing
•    Sleep-disordered breathing is a risk factor and a consequence of 
stroke and has been linked with poorer long-term outcome and 
increased long-term stroke mortality.33
•    Stroke patients may have sleep-disordered breathing, mostly in 
the form of obstructive sleep apnoea (OSA). This can improve 
spontaneously after stroke, but may need treatment. Continuous 
positive airway pressure is the treatment of choice for OSA.
12.13 Postmenopausal oestrogen replacement 
therapy
Hormone replacement therapy does not protect against vascular 
events and may increase stroke severity.34
Recommendations
•    Tight control of blood pressure <130/80 mmHg is recommended 
for secondary stroke prevention (Class I, level A).
•    Diabetic patients should be managed with lifestyle modification 
and individualised pharmacological therapy aiming for near 
normoglycaemic values. (Class IV, GCP).
•    patients with atherosclerotic stroke (non-cardio-embolic stroke) 
or TiA and non-fasting total cholesterol >3.5 mmol/l should be 
treated with a statin (Class I, level A).
•    in the absence of documented efficacy of low-dosage statin 
treatment for secondary stroke prevention, the strength used in 
the secondary prevention trials should be prescribed (e.g. 40 mg 
simvastatin).
•    All health care providers should strongly advise patients with 
stroke or TiA to stop smoking and avoid environmental tobacco 
smoke (Class III, level C).
•    The heavy use of alcohol (>2 drinks/day for men, and 1 drink/
day for non-pregnant women) should be discouraged (Class IV, 
GCP).
•    Weight reduction is recommended for patients with a BMi >25 kg/
m2, and a waist circumference >102 cm for men and >88 cm for 
women (Class I level B).
•    regular physical activity is recommended (Class IV, GCP). 
patients with disability should be encouraged to engage in a 
supervised therapeutic exercise regimen.
•    patients with ischaemic stroke or TiA not requiring anticoagulation 
should receive platelet-inhibiting medication (Class I, level A).
•    Aspirin 75 - 150 mg/day remains an inexpensive and cost-effective 
antiplatelet treatment for secondary prevention of stroke in a 
developing country.
•    Alternatively, extended-release dipyridamole plus aspirin or 
clopidogrel can be considered (Class I, level A), particularly in 
patients with recurrent vascular events, if already treated with 
aspirin, and in patients at high risk for cerebrovascular events.
•    The combination of aspirin and clopidogrel is not recommended 
in patients with recent ischaemic stroke, except in patients with 
specific indications (e.g. unstable angina or non-Q-wave Mi, or 
recent stenting) (Class I, level A).
•    patients allergic to aspirin should receive clopidogrel.
•    Anticoagulation with dose-adjusted warfarin is recommended for 
patients with cardio-embolic ischaemic stroke or TiA associated 
with intermittent or persistent AF (Class I, level A).
•    patients with cardio-embolic stroke unrelated to AF should receive 
anticoagulants (inr 2.0 - 3.0) if the risk of recurrence is high 
(Class III, level C).
•    patients unable to take oral anticoagulants should receive platelet-
inhibiting medication (Class IV, GCP).
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•    For patients with cardio-embolic stroke or TiA following acute 
myocardial infarction, oral anticoagulation between 3 and 12 
months is reasonable (Class IV, GCP).
•    endovascular closure of pFO may be considered in patients with 
cryptogenic stroke and high risk pFO (Class IV, GCP).
•    Sleep-disordered breathing such as obstructive sleep apnoea should 
be treated with continuous positive airway pressure breathing 
(Class III, level GCP).
•    Hormone replacement therapy is not recommended for the 
secondary prevention of stroke (Class I, level A).
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13. stroke rehabilitation
13.1 Definition
•    Stroke rehabilitation is a goal-orientated process which attempts to 
obtain maximum function in patients who have had strokes and 
who suffer from a combination of physical, cognitive and language 
disabilities.
•    The rehabilitation process is best performed using an 
interdisciplinary approach by experts who have experience and 
understanding of the particular issues facing stroke patients.1
13.2 Goals
•    The ultimate goal of rehabilitation is to enable patients to resume 
their pre-morbid function both within family and community life 
and, if possible, at work. Where this is not possible, alternative 
strategies should be considered.
•    if full resumption of work activities is not possible, skills retraining 
may be considered.
•    in patients who have significant permanent disabilities, 
consideration must be aimed at reducing the burden of care for 
the family and helping the patient to become as independent as 
possible.
•    With patients who have had severe strokes with poor recovery, the 
provision and training of caregivers should be addressed by the 
rehabilitation team and, in very poor outcomes, institutionalisation 
may be recommended for the patient’s ultimate care. Decisions 
about home care v. institutionalisation must involve all parties and 
should take into account financial and social circumstances.
•    rehabilitation can be organised on an in- or outpatient basis.
•    in the South African context, outpatient therapy very rarely 
achieves the intensity of inpatient rehabilitation units. Therefore, 
where necessary, inpatient therapy may be preferable. Criteria 
for admission to inpatient therapy vary. Typically, where patients 
require three modalities of intervention, or where patients are 
unable to transfer independently, inpatient rehabilitation is 
justified; this is particularly true in patients with moderate and 
severe strokes.
•    The majority of stroke patients in South Africa are treated in the 
public health care sector where there is currently a shortage or 
even absence of inpatient rehabilitation beds for stroke patients, 
especially in rural and remote areas. under such circumstances, 
efforts are currently underway to improve home-based care and 
rehabilitation as well as community-based rehabilitation and the 
use of ‘step-down’ facilities where available.
13.3 Interdisciplinary approach
•    A key characteristic of the stroke unit model of care is rehabilitation 
delivered by a specialised multidisciplinary team who communicate 
with each other regularly and use their varying expertise to work 
towards common goals.1,2
•    Admission to a dedicated stroke unit improves outcomes for all 
strokes irrespective of age, sex and severity.3
•    There are also long-term functional benefits of dedicated stroke 
unit care; follow-up at 5 and 10 years has revealed persisting 
efficacy compared with controls.4,5
•    early initiation of rehabilitation interventions has been associated with 
improved outcome at discharge from hospital and at follow-up.1
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•    The financial and social implications of prolonged hospitalisation 
have prompted increasing interest in services to facilitate early 
return to the community.
•    A multidisciplinary team approach can significantly reduce bed 
days for selected stroke patients who have mild or moderate 
impairment at baseline, but mortality has been shown to increase 
when patients were discharged early with only generic community 
support.6-8
•    The rehabilitation team usually consists of the following personnel: 
physiotherapist, occupational therapist, speech and language 
therapist, psychologist, social worker, dietician, nurses who have 
training and experience in rehabilitation, and medical practitioner 
with an understanding of the stroke and rehabilitation processes.
•    The patient should be fully assessed by each member or the 
team within 24 hours of the onset of the stroke. After the initial 
assessment, therapy strategies are planned and a decision for in- or 
outpatient therapy is suggested.
•    An essential aspect of the interdisciplinary team approach is the 
issue of interaction and communication with both the patient and 
the family.
•    ideally, communication between the rehabilitation team, family 
and patient should be formalised at a family meeting within the 
first week of therapy. The aim of the family meeting is to educate 
the patient and family on the circumstances of the particular 
patient and the anticipated outcomes.
13.4 Education
education of the patient, family members and caregivers is an 
important aspect of stroke rehabilitation, requiring participation by 
all members of the team. issues that need to be discussed include 
causes of stroke and investigations, rehabilitation interventions, 
prevention of repeated strokes, outcomes after stroke, necessary 
lifestyle changes, sexuality, impact on family, resumption of driving, 
participation in leisure activities, and complications.
13.5 Discharge planning
•    Discharge planning is an integral part of rehabilitation.
•    At an early stage, provisional plans for discharge should be 
considered. These plans may change during the process of 
rehabilitation.
•    early planning will enable families to implement changes that 
may be necessary within the home, such as alterations to toilet 
and bath facilities and the construction of ramps, where necessary. 
Special consideration must be given to patients who are returning 
to informal settlements and shacks, with no access to basic 
amenities.
•    in urban inpatient facilities, it is common practice to allow 
patients to go home for one or two nights prior to their discharge, 
so enabling the patient and the family to assess what difficulties 
are encountered in their home environment and to use the 
rehabilitation team to address these problems and correct them 
before final discharge. in a rural setting, a home visit by a member 
of the rehabilitation team prior to discharge may assist in planning 
a home adaptation programme. As far as possible, patients in rural 
areas should also have the opportunity to go home for one or two 
nights prior to discharge.
•    Discharge planning should also include the possibility of returning 
to work and implementing changes in the work place which may 
be appropriate for the patient.
•    At the time of discharge, appropriate referral to various health care 
professionals and support groups is important. This may include 
a delayed referral to an occupational therapist who specialises in 
performing work assessments.
•    liaison between the rehabilitation team and employers is also 
important, and is usually performed by the social worker.
•    in patients where significant and permanent disability is anticipated, 
the concept of caregiver employment and training should be 
implemented timeously.
13.6 Post-discharge rehabilitation
•    rehabilitation is a protracted process and, once the patient is 
discharged from hospital or from the rehabilitation unit, ongoing 
therapy may be necessary. Appropriate referrals for therapy should 
be made before the time of discharge. A meta-analysis showed that 
continued rehabilitation after discharge during the first year after 
stroke reduces the risk of deterioration in function and improves 
daily living activities.9 The interventions included occupational 
therapy, physiotherapy, and multidisciplinary teams, and therefore 
no definitive statement can be made concerning the optimal mode 
of service delivery.
•    it is common practice to re-assess patients some time after 
discharge from their rehabilitation programme to assess their 
progress and to address any new difficulties which have been 
identified by patients and their families.
13.7 Rehabilitation interventions
13.7.1 Physiotherapy
•    early intervention by physiotherapists will be concerned with 
appropriate positioning of hemiplegic patients and attempts at 
early mobilisation and mobility.
•    Safety of the patient and the prevention of falls and injury are of 
paramount importance at all times.
•    Communication between physiotherapist and nursing staff is 
important in maintaining levels of safety.
•    There is no clearly superior model of physiotherapy for stroke 
rehabilitation, but some evidence exists to support specific 
interventions.10,11
•    Several groups have shown that strength can be improved in a 
dose-dependent manner, without increasing spasticity.12
•    The South African Society of physiotherapy has produced a 
document detailing its recommended physiotherapy management 
of stroke patients (‘CvA essential healthcare package’).
13.7.2 Occupational therapy (OT)
•    initially, this concerns resumption of daily activities such as 
grooming, toileting, washing, shaving, dressing and eating.
•    issues of neglect, spatial perception problems and visual difficulties 
must be considered in the course of OT sessions.
•    Assistive devices may be required; and it is the occupational 
therapist’s role to identify which devices are required. These may 
include equipment such as wheelchairs, walking aids and bath and 
shower aids.
•    A systematic review of 9 trials comparing occupational therapy-
based ADl therapy with usual care reported improved functional 
outcomes in the active intervention group.13 The data do not justify 
conclusions on the optimal mode of OT delivery.
•    A meta-analysis of community-based OT trials found improved 
performance on ADl measures. The greatest effects were seen in 
older patients and with the use of targeted interventions.14
13.7.3 speech therapy
•    An important role of the speech and language therapist in early 
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intervention is the assessment of swallowing safety. This is 
extremely important; failure to identify and implement appropriate 
measures for swallowing safety may result in significant increases 
in morbidity and mortality.
•    in patients who have language difficulties, the involvement of 
speech and language therapists from the onset is important. 
Alternative communication techniques may be explored, and 
education of family members, particularly about the levels of 
frustration experienced by people who are aphasic, must be 
discussed.
13.7.4 Diet
involvement of a dietician early in the recovery phase is important. 
Malnutrition has been shown to be a significant problem in 
patients with strokes, either because of difficulty with swallowing 
or the inability of patients to express their needs about nutritional 
requirements (aphasic patients).
13.7.5 Psychological support
•    Stroke often has a devastating effect on patients and their families. 
The psychologist may have an important role in counselling the 
stroke patient and family members about adapting to disability, 
and new roles within the family and workplace.
•    Depression is a common consequence of stroke.15 particular issues 
which contribute to depression include fear of further strokes, loss 
of independence, loss of earning power, altered social dynamics 
and loss of function.
•    post-stroke depression is associated with poor rehabilitation results 
and ultimately poor outcome.16,17
•    in clinical practice, only a minority of depressed patients are 
diagnosed, and even fewer are treated.18
•    predictors of post-stroke depression in the rehabilitation setting 
include increasing physical disability, cognitive impairment and 
stroke severity.17
•    The routine use of antidepressants is not recommended.
•    Where depression has been identified as a persistent problem, 
intervention by psychotherapists and the use of antidepressant 
medication should be considered.
•    Antidepressant drugs such as selective serotonin reuptake 
inhibitors (SSris) and heterocyclics can improve mood after 
stroke, but there is less evidence that these agents can effect full 
remission of a major depressive episode or prevent depression. 
SSris are better tolerated than heterocyclics.19-21
•    There is no good evidence to recommend psychotherapy for 
treatment or prevention of post-stroke depression, although such 
therapy can elevate mood.22
•    emotionalism is a distressing symptom for patients and carers. 
SSris may reduce emotional outbursts but effects on quality of life 
are not clear.23
13.7.6 Counselling on sexuality
•    Sexuality can suffer after a stroke.
•    Change in body image, underlying physical limitations, and 
co-morbid vascular disease may be compounded by side-effects 
of medications.24
•    issues of sexuality and intimacy should be discussed with patients, 
preferably by an appropriately trained professional.25
•    provision of support and information is important: many patients 
wrongly fear that resuming an active sex life may result in further 
stroke.26
13.8 Complications affecting rehabilitation
•    rehabilitation can be compromised by complications that may 
be strong predictors of poor functional outcome and mortality. 
Common complications during inpatient rehabilitation include 
depression, shoulder pain, thalamic (central) pain, spasticity, falls, 
urinary disturbances and aspiration pneumonia.27
•    post-stroke shoulder pain is common especially in patients 
with impaired arm function and poor functional status, and is 
associated with poorer outcome.28
•    passive movement of a paretic limb may be preventive.29
•    electrical stimulation is commonly used for treatment, but its 
efficacy is unproven.30 A Cochrane systematic review found 
insufficient data to recommend the use of orthotic devices for 
shoulder subluxation, despite a trend towards efficacy of arm 
strapping the affected limb.31
•    lamotrigine and gabapentin may be considered for neuropathic 
pain.32 They appear to be well tolerated, but cognitive side-effects 
should be considered.
•    Spasticity in the chronic phase may adversely affect ADl and 
quality of life.33 posture and movement therapy, relaxing therapy, 
splints and supports are all commonly employed, but a sound 
evidence base is lacking.34 pharmacotherapy with botulinum toxin 
has proven effects on muscle tone in arms and legs, but functional 
benefits are less well studied.35-37 Oral agents are limited in their 
use because of side-effects.38
13.9 Eligibility for rehabilitation
•    in South Africa, access to and availability of either inpatient or 
outpatient rehabilitation varies considerably, as does the duration 
and intensity of the rehabilitation programme. This depends not 
only the severity of the neurological deficits but also on a number 
of other factors relevant to developing counties: whether or not 
the stroke patient has private health insurance (a minority of the 
country’s stroke patients have), their geographical location, and 
availability of trained rehabilitation therapists and public or private 
rehabilitation facilities in the area (most are located in the larger 
metropolitan areas).
•    An important predictor of rehabilitation outcome is initial stroke 
severity.16 pre-stroke disability is clearly also a strong determinant 
of outcome.39
•    exclusion from rehabilitation on the basis of pre-stroke dependence 
remains a contentious issue.40,41
•    limited facilities and resource constraints in South Africa 
frequently preclude patients with pre-stroke dependency or other 
reasons deemed to be prognostic of a very poor outcome from 
access to inpatient rehabilitation.
•    patients with the most severe cognitive or physical impairments 
have been excluded from most rehabilitation trials, and therefore 
caution is required in extrapolating results to this group.42
•    For those unable to participate actively, passive movements to 
prevent contractures or pressure sores have been recommended.43
13.10 Development of a model for stroke care 
in under-resourced settings
•    in-service training of health care professionals and home-
based carers in all aspects of stroke care would be an important 
component in the future planning and implementation of both 
hospital and community-based stroke services in an under-
resourced setting such as South Africa.
•    Any model of community-based stroke care in South African 
settings should include a system of stroke education for caregivers 
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and patients, and should implement structures that strengthen the 
level of home-based care and training.
•    Awareness of stroke and cardiovascular risk factors, particularly 
hypertension, needs to be fostered through improved community 
education. nurse practitioners and home-based carers could play 
an important role in checking Bp and monitoring treatment and 
compliance after discharge from hospital.
•    in-service training of both urban and rural-based health care 
professionals in protocols of acute stroke management might 
reduce in-hospital complications, morbidity and mortality, 
providing optimal potential for an improved outcome following 
discharge into the community.
•    in the absence of adequate numbers of health workers available 
for rehabilitation in such communities, caregivers are the likely 
candidates to adopt this surrogate role, and could be trained to be 
more active in the rehabilitation process.44
•    These relatively simple interventions have the potential to improve 
stroke outcomes and relieve caregiver strain in the South African 
setting.
Recommendations
•    early initiation of rehabilitation is recommended (Class III, level 
C).
•    early discharge from stroke unit care is possible in medically 
stable patients with mild or moderate impairment, providing that 
rehabilitation is delivered in the community by a multidisciplinary 
team with stroke expertise (Class I, level A).
•    rehabilitation should be continued after discharge during the first 
year after stroke (Class II, level A).
•    Any model of community-based stroke care in South African 
settings should include a system of stroke education for caregivers 
and patients, and should implement structures that strengthen the 
level of home-based care and training (Class IV, GCP).
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